{"cells":[{"cell_type":"markdown","metadata":{"id":"XtRq1olzGK8M"},"source":["# 0. Google Colab Setup"]},{"cell_type":"code","execution_count":1,"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"executionInfo":{"elapsed":17039,"status":"ok","timestamp":1712361244931,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"iP6VuWPOGBoK","outputId":"2cc8f893-b082-4c8c-b3b1-461d959c1a1b"},"outputs":[{"name":"stdout","output_type":"stream","text":["Mounted at /content/drive\n"]}],"source":["import os\n","from google.colab import drive\n","drive.mount('/content/drive')"]},{"cell_type":"code","execution_count":2,"metadata":{"executionInfo":{"elapsed":4,"status":"ok","timestamp":1712361244931,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"LsFT59mNGWC5"},"outputs":[],"source":["os.chdir('./drive/MyDrive/NLP MedLM project')"]},{"cell_type":"code","execution_count":4,"metadata":{"executionInfo":{"elapsed":4,"status":"ok","timestamp":1712361244932,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"heq4FcDwGpzh"},"outputs":[],"source":["# unzip dataset zipfile\n","# !unzip './dataset/MedQuAD-master.zip'"]},{"cell_type":"code","execution_count":5,"metadata":{"executionInfo":{"elapsed":255,"status":"ok","timestamp":1712361245184,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"r4oh8AjsHhmp"},"outputs":[],"source":["# !unzip './dataset/medical-question-answer-data-master.zip'"]},{"cell_type":"markdown","metadata":{"id":"Rjm2ibZsHwVz"},"source":["# 1. Process MedQuAD data"]},{"cell_type":"code","execution_count":null,"metadata":{"id":"bO2QipEgKQ0K"},"outputs":[],"source":["import xml.etree.ElementTree as ET\n","\n","import re\n","from tqdm import tqdm\n","\n","import pandas as pd"]},{"cell_type":"code","execution_count":null,"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"executionInfo":{"elapsed":212,"status":"ok","timestamp":1710875760804,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"9RVSkd9RH1LC","outputId":"66b01918-a228-4ed0-fc5d-63fa79f47af5"},"outputs":[{"data":{"text/plain":["['10_MPlus_ADAM_QA',\n"," '11_MPlusDrugs_QA',\n"," '12_MPlusHerbsSupplements_QA',\n"," '1_CancerGov_QA',\n"," '2_GARD_QA',\n"," '3_GHR_QA',\n"," '4_MPlus_Health_Topics_QA',\n"," '5_NIDDK_QA',\n"," '6_NINDS_QA',\n"," '7_SeniorHealth_QA',\n"," '8_NHLBI_QA_XML',\n"," '9_CDC_QA']"]},"execution_count":14,"metadata":{},"output_type":"execute_result"}],"source":["MED_PATH = './dataset/MedQuAD-master'\n","\n","file_names = [fn for fn in os.listdir(MED_PATH) if fn[0].isdigit()]"]},{"cell_type":"code","execution_count":null,"metadata":{"id":"sn0k2dOJLVy-"},"outputs":[],"source":["# clean up answers with unwanted tokens and long whitespaces\n","def clean_up(answer):\n","  answer = re.sub(' +', ' ', answer)\n","  answer = answer.replace(\"Key Points\", \"\")\n","  answer = answer.replace(\"\\n\", \"\")\n","  answer = answer.replace(\"-\", \"\")\n","  answer = answer.replace(\"\\t\", \"\")\n","  return answer\n","\n","def parse_xml(file_name):\n","  tree = ET.parse(file_name)\n","  root = tree.getroot()\n","\n","  # one xml file with only one focus\n","  try:\n","    focus = root.find('Focus').text.strip()\n","  except AttributeError:\n","    focus = None\n","\n","  # one xml file may have more than one QA pairs\n","  qa_pairs = []\n","  for qa_pair in root.findall('QAPairs/QAPair'):\n","    question = qa_pair.find('Question').text.strip()\n","    # may have no answer situation\n","    try:\n","      answer = qa_pair.find('Answer').text.strip()\n","      answer = clean_up(answer)\n","    except AttributeError:\n","      answer = None\n","    qa_pairs.append((question, answer, focus))\n","\n","  return qa_pairs"]},{"cell_type":"code","execution_count":null,"metadata":{"id":"m1pzAVJXN0qN"},"outputs":[],"source":["# process all data\n","def process_files(path):\n","  processed_data = []\n","  xml_files = [os.path.join(path, f) for f in os.listdir(path) if f.endswith('.xml')]\n","  for xml_file in tqdm(xml_files, desc=f\"Processing files in {path}\"):\n","    qa_pairs = parse_xml(xml_file)\n","    processed_data.extend(qa_pairs)\n","\n","  return processed_data"]},{"cell_type":"code","execution_count":null,"metadata":{"id":"wZkXyYj8UG4d"},"outputs":[],"source":["def process_folders(root_path):\n","  data = []\n","  folders = [f.path for f in os.scandir(root_path) if f.is_dir()]\n","\n","  for folder in folders:\n","    processed_data = process_files(folder)\n","    data.extend(processed_data)\n","\n","  # convert to pandas dataframe\n","  df = pd.DataFrame(data, columns=['Question', 'Answer', 'Focus'])\n","  return df"]},{"cell_type":"code","execution_count":null,"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"executionInfo":{"elapsed":214668,"status":"ok","timestamp":1710880784289,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"1wUs_a0bUuWm","outputId":"8efdef6a-5407-4236-db8d-6b5d04c5bbdb"},"outputs":[{"name":"stderr","output_type":"stream","text":["Processing files in ./dataset/MedQuAD-master/10_MPlus_ADAM_QA: 100%|██████████| 4366/4366 [01:44<00:00, 41.77it/s] \n","Processing files in ./dataset/MedQuAD-master/11_MPlusDrugs_QA: 100%|██████████| 1312/1312 [00:24<00:00, 53.65it/s] \n","Processing files in ./dataset/MedQuAD-master/12_MPlusHerbsSupplements_QA: 100%|██████████| 99/99 [00:00<00:00, 284.93it/s]\n","Processing files in ./dataset/MedQuAD-master/1_CancerGov_QA: 100%|██████████| 116/116 [00:00<00:00, 132.39it/s]\n","Processing files in ./dataset/MedQuAD-master/2_GARD_QA: 100%|██████████| 2685/2685 [00:55<00:00, 48.32it/s] \n","Processing files in ./dataset/MedQuAD-master/3_GHR_QA: 100%|██████████| 1086/1086 [00:12<00:00, 86.52it/s] \n","Processing files in ./dataset/MedQuAD-master/4_MPlus_Health_Topics_QA: 100%|██████████| 981/981 [00:11<00:00, 82.73it/s] \n","Processing files in ./dataset/MedQuAD-master/5_NIDDK_QA: 100%|██████████| 157/157 [00:01<00:00, 139.62it/s]\n","Processing files in ./dataset/MedQuAD-master/6_NINDS_QA: 100%|██████████| 277/277 [00:01<00:00, 153.16it/s]\n","Processing files in ./dataset/MedQuAD-master/7_SeniorHealth_QA: 100%|██████████| 48/48 [00:00<00:00, 173.04it/s]\n","Processing files in ./dataset/MedQuAD-master/8_NHLBI_QA_XML: 100%|██████████| 88/88 [00:00<00:00, 205.11it/s]\n","Processing files in ./dataset/MedQuAD-master/9_CDC_QA: 100%|██████████| 59/59 [00:00<00:00, 237.96it/s]\n","Processing files in ./dataset/MedQuAD-master/.ipynb_checkpoints: 0it [00:00, ?it/s]\n"]}],"source":["med_df = process_folders(MED_PATH)"]},{"cell_type":"code","execution_count":null,"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":143},"executionInfo":{"elapsed":290,"status":"ok","timestamp":1710880784577,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"2RC3IQw5XYSg","outputId":"7414aa55-a067-44b5-d9ab-7460807d2310"},"outputs":[{"data":{"application/vnd.google.colaboratory.intrinsic+json":{"summary":"{\n  \"name\": \"med_df\",\n  \"rows\": 47441,\n  \"fields\": [\n    {\n      \"column\": \"Question\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 44603,\n        \"samples\": [\n          \"What is (are) GLUT1 deficiency syndrome ?\",\n          \"What to do in case of emergency or overdose of Cariprazine ?\",\n          \"Do you have information about Uric acid - blood\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Answer\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 15809,\n        \"samples\": [\n          \"Some people may experience relief from symptoms of indigestion by  eating several small, lowfat meals throughout the day at a slow pace  refraining from smoking  abstaining from consuming coffee, carbonated beverages, and alcohol  stopping use of medications that may irritate the stomach liningsuch as aspirin or antiinflammatory drugs  getting enough rest  finding ways to decrease emotional and physical stress, such as relaxation therapy or yoga The doctor may recommend overthecounter antacids or medications that reduce acid production or help the stomach move food more quickly into the small intestine. Many of these medications can be purchased without a prescription. Nonprescription medications should only be used at the dose and for the length of time recommended on the label unless advised differently by a doctor. Informing the doctor when starting a new medication is important. Antacids, such as AlkaSeltzer, Maalox, Mylanta, Rolaids, and Riopan, are usually the first drugs recommended to relieve symptoms of indigestion. Many brands on the market use different combinations of three basic saltsmagnesium, calcium, and aluminumwith hydroxide or bicarbonate ions to neutralize the acid in the stomach. Antacids, however, can have side effects. Magnesium salt can lead to diarrhea, and aluminum salt may cause constipation. Aluminum and magnesium salts are often combined in a single product to balance these effects. Calcium carbonate antacids, such as Tums, Titralac, and Alka2, can also be a supplemental source of calcium, though they may cause constipation. H2 receptor antagonists (H2RAs) include ranitidine (Zantac), cimetidine (Tagamet), famotidine (Pepcid), and nizatidine (Axid) and are available both by prescription and overthecounter. H2RAs treat symptoms of indigestion by reducing stomach acid. They work longer than but not as quickly as antacids. Side effects of H2RAs may include headache, nausea, vomiting, constipation, diarrhea, and unusual bleeding or bruising. Proton pump inhibitors (PPIs) include omeprazole (Prilosec, Zegerid), lansoprazole (Prevacid), pantoprazole (Protonix), rabeprazole (Aciphex), and esomeprazole (Nexium) and are available by prescription. Prilosec is also available in overthecounter strength. PPIs, which are stronger than H2RAs, also treat indigestion symptoms by reducing stomach acid. PPIs are most effective in treating symptoms of indigestion in people who also have GERD. Side effects of PPIs may include back pain, aching, cough, headache, dizziness, abdominal pain, gas, nausea, vomiting, constipation, and diarrhea. Prokinetics such as metoclopramide (Reglan) may be helpful for people who have a problem with the stomach emptying too slowly. Metoclopramide also improves muscle action in the digestive tract. Prokinetics have frequent side effects that limit their usefulness, including fatigue, sleepiness, depression, anxiety, and involuntary muscle spasms or movements. If testing shows the type of bacteria that causes peptic ulcer disease, the doctor may prescribe antibiotics to treat the condition.\",\n          \"  There are different types of treatment for patients with childhood astrocytoma.  Children with astrocytomas should have their treatment planned by a team of health care providers who are experts in treating childhood brain tumors.  Childhood brain tumors may cause signs or symptoms that begin before the cancer is diagnosed and continue for months or years.  Some cancer treatments cause side effects months or years after treatment has ended.  Six types of treatment are used:  Surgery  Observation  Radiation therapy  Chemotherapy  Highdose chemotherapy with stem cell transplant  Targeted therapy  New types of treatment are being tested in clinical trials.  Other drug therapy  If fluid builds up around the brain and spinal cord, a cerebrospinal fluid diversion procedure may be done.  Patients may want to think about taking part in a clinical trial.  Patients can enter clinical trials before, during, or after starting their cancer treatment.  Followup tests may be needed.   There are different types of treatment for patients with childhood astrocytoma. Different types of treatment are available for children with astrocytomas. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment.   Children with astrocytomas should have their treatment planned by a team of health care providers who are experts in treating childhood brain tumors. Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric oncologist works with other healthcare providers who are experts in treating children with brain tumors and who specialize in certain areas of medicine. These may include the following specialists:  Pediatrician.  Pediatric neurosurgeon.  Neurologist.  Neuropathologist.  Neuroradiologist.  Rehabilitation specialist.  Radiation oncologist.  Endocrinologist.  Psychologist.   Childhood brain tumors may cause signs or symptoms that begin before the cancer is diagnosed and continue for months or years. Signs or symptoms caused by the tumor may begin before diagnosis. These signs or symptoms may continue for months or years. It is important to talk with your child's doctors about signs or symptoms caused by the tumor that may continue after treatment.   Some cancer treatments cause side effects months or years after treatment has ended. Side effects from cancer treatment that begin during or after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include the following:  Physical problems.  Changes in mood, feelings, thinking, learning, or memory.  Second cancers (new types of cancer). Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. (See the PDQ summary on Late Effects of Treatment for Childhood Cancer for more information.)   Six types of treatment are used: Surgery Surgery is used to diagnose and treat childhood astrocytoma, as discussed in the General Information section of this summary. If cancer cells remain after surgery, further treatment depends on:  Where the remaining cancer cells are.  The grade of the tumor.  The age of the child. Even if the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that remain. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy. Observation Observation is closely monitoring a patients condition without giving any treatment until signs or symptoms appear or change. Observation may be used:  If the patient has no symptoms, such as patients with neurofibromatosis type1.  If the tumor is small and is found when a different health problem is being diagnosed or treated.  After the tumor is removed by surgery until signs or symptoms appear or change. Radiation therapy Radiation therapy is a cancer treatment that uses highenergy xrays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:  External radiation therapy uses a machine outside the body to send radiation toward the cancer. Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. These types of radiation therapy include the following:  Conformal radiation therapy: Conformal radiation therapy is a type of external radiation therapy that uses a computer to make a 3dimensional (3D) picture of the tumor and shapes the radiation beams to fit the tumor.  Intensitymodulated radiation therapy (IMRT): IMRT is a type of 3dimensional (3D) external radiation therapy that uses a computer to make pictures of the size and shape of the tumor. Thin beams of radiation of different intensities (strengths) are aimed at the tumor from many angles.  Stereotactic radiation therapy: Stereotactic radiation therapy is a type of external radiation therapy. A rigid head frame is attached to the skull to keep the head still during the radiation treatment. A machine aims radiation directly at the tumor. The total dose of radiation is divided into several smaller doses given over several days. This procedure is also called stereotactic externalbeam radiation therapy and stereotaxic radiation therapy.  Proton beam radiation therapy: Protonbeam therapy is a type of highenergy, external radiation therapy. A radiation therapy machine aims streams of protons (tiny, invisible, positivelycharged particles) at the cancer cells to kill them.  Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer. The way the radiation therapy is given depends on the type of tumor and where the tumor formed in the brain or spinal cord. External radiation therapy is used to treat childhood astrocytomas. Radiation therapy to the brain can affect growth and development, especially in young children. For children younger than 3 years, chemotherapy may be given instead, to delay or reduce the need for radiation therapy. Chemotherapy Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). Combination chemotherapy is the use of more than one anticancer drug. The way the chemotherapy is given depends on the type of tumor and where the tumor formed in the brain or spinal cord. Systemic combination chemotherapy is used in the treatment of children with astrocytoma. Highdose chemotherapy may be used in the treatment of children with newly diagnosed highgrade astrocytoma. Highdose chemotherapy with stem cell transplant Highdose chemotherapy with stem cell transplant is a way of giving high doses of chemotherapy and replacing blood forming cells destroyed by the cancer treatment. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the chemotherapy is completed, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells. For highgrade astrocytoma that has come back after treatment, highdose chemotherapy with stem cell transplant is used if there is only a small amount of tumor. Targeted therapy Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells without harming normal cells. There are different types of targeted therapy:  Monoclonal antibody therapy uses antibodies made in the laboratory, from a single type of immune system cell, to stop cancer cells. These antibodies can identify substances on cancer cells or normal substances that may help cancer cells grow. The antibodies attach to the substances and kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion into a vein. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. There are different types of monoclonal antibody therapy:  Vascular endothelial growth factor (VEGF) inhibitor therapy: Cancer cells make a substance called VEGF, which causes new blood vessels to form (angiogenesis) and helps the cancer grow. VEGF inhibitors block VEGF and stop new blood vessels from forming. This may kill cancer cells because they need new blood vessels to grow. Bevacizumab is a VEGF inhibitor and angiogenesis inhibitor being used to treat childhood astrocytoma.  Immune checkpoint inhibitor therapy: PD1 is a protein on the surface of T cells that helps keep the bodys immune responses in check. When PD1 attaches to another protein called PDL1 on a cancer cell, it stops the T cell from killing the cancer cell. PD1 inhibitors attach to PDL1 and allow the T cells to kill cancer cells. PD1 inhibitors are being studied to treat highgrade astrocytoma that has recurred.  Protein kinase inhibitors work in different ways. There are several kinds of protein kinase inhibitors.  mTOR inhibitors stop cells from dividing and may prevent the growth of new blood vessels that tumors need to grow. Everolimus and sirolimus are mTOR inhibitors used to treat childhood subependymal giant cell astrocytomas. mTOR inhibitors also are being studied to treat lowgrade astrocytoma that has recurred.  BRAF inhibitors block proteins needed for cell growth and may kill cancer cells. The BRAF inhibitor dabrafenib is being studied to treat lowgrade astrocytoma that has recurred. Vemurafenib and dabrafenib have been used to treat highgrade astrocytomas that have recurred but more study is needed to know how well they work in children.  MEK inhibitors block proteins needed for cell growth and may kill cancer cells. MEK inhibitors such as selumetinib are being studied to treat lowgrade astrocytoma that has recurred. See Drugs Approved for Brain Tumors for more information.   New types of treatment are being tested in clinical trials. This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website. Other drug therapy Lenalidomide is a type of angiogenesis inhibitor. It prevents the growth of new blood vessels that are needed by a tumor to grow.   If fluid builds up around the brain and spinal cord, a cerebrospinal fluid diversion procedure may be done. Cerebrospinal fluid diversion is a method used to drain fluid that has built up around the brain and spinal cord. A shunt (long, thin tube) is placed in a ventricle (fluidfilled space) of the brain and threaded under the skin to another part of the body, usually the abdomen. The shunt carries extra fluid away from the brain so it may be absorbed elsewhere in the body.   Patients may want to think about taking part in a clinical trial. For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment. Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment. Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.   Patients can enter clinical trials before, during, or after starting their cancer treatment. Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment. Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from NCI's listing of clinical trials.   Followup tests may be needed. Some of the tests that were done to diagnose the cancer or to find out the stage of the cancer may be repeated. (See the General Information section for a list of tests.) Some tests will be repeated in order to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests. Regular MRIs will continue to be done after treatment has ended. The results of the MRI can show if your child's condition has changed or if the astrocytoma has recurred (come back). If the results of the MRI show a mass in the brain, a biopsy may be done to find out if it is made up of dead tumor cells or if new cancer cells are growing.   Treatment Options for Childhood Astrocytomas   Newly Diagnosed Childhood LowGrade Astrocytomas When the tumor is first diagnosed, treatment for childhood lowgrade astrocytoma depends on where the tumor is, and is usually surgery. An MRI is done after surgery to see if there is tumor remaining. If the tumor was completely removed by surgery, more treatment may not be needed and the child is closely watched to see if signs or symptoms appear or change. This is called observation. If there is tumor remaining after surgery, treatment may include the following:  Observation.  A second surgery to remove the tumor.  Radiation therapy, which may include conformal radiation therapy, intensitymodulated radiation therapy, proton beam radiation therapy, or stereotactic radiation therapy, when the tumor begins to grow again.  Combination chemotherapy with or without radiation therapy. In some cases, observation is used for children who have a visual pathway glioma. In other cases, treatment may include surgery to remove the tumor, radiation therapy, or chemotherapy. A goal of treatment is to save as much vision as possible. The effect of tumor growth on the child's vision will be closely followed during treatment. Children with neurofibromatosis type 1 (NF1) may not need treatment unless the tumor grows or signs or symptoms, such as vision problems, appear. When the tumor grows or signs or symptoms appear, treatment may include surgery to remove the tumor, radiation therapy, and/or chemotherapy. Children with tuberous sclerosis may develop benign (not cancer) tumors in the brain called subependymal giant cell astrocytomas (SEGAs). Targeted therapy with everolimus or sirolimus may be used instead of surgery, to shrink the tumors. Check the list of NCIsupported cancer clinical trials that are now accepting patients with childhood lowgrade untreated astrocytoma or other tumor of glial origin. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.   Recurrent Childhood LowGrade Astrocytomas When lowgrade astrocytoma recurs after treatment, it usually comes back where the tumor first formed. Before more cancer treatment is given, imaging tests, biopsy, or surgery are done to find out if there is cancer and how much there is. Treatment of recurrent childhood lowgrade astrocytoma may include the following:  A second surgery to remove the tumor, if surgery was the only treatment given when the tumor was first diagnosed.  Radiation therapy to the tumor only, if radiation therapy was not used when the tumor was first diagnosed. Conformal radiation therapy may be given.  Chemotherapy, if the tumor recurred where it cannot be removed by surgery or the patient had radiation therapy when the tumor was first diagnosed.  Targeted therapy with a monoclonal antibody (bevacizumab) with or without chemotherapy.  A clinical trial of targeted therapy with a BRAF inhibitor (dabrafenib), an mTOR inhibitor (everolimus), or a MEK inhibitor (selumetinib).  A clinical trial of lenalidomide. Check the list of NCIsupported cancer clinical trials that are now accepting patients with recurrent childhood astrocytoma or other tumor of glial origin. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.   Newly Diagnosed Childhood HighGrade Astrocytomas Treatment of childhood highgrade astrocytoma may include the following:  Surgery to remove the tumor, followed by chemotherapy and/or radiation therapy.  A clinical trial of a new treatment. Check the list of NCIsupported cancer clinical trials that are now accepting patients with childhood highgrade untreated astrocytoma or other tumor of glial origin. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.   Recurrent Childhood HighGrade Astrocytomas When highgrade astrocytoma recurs after treatment, it usually comes back where the tumor first formed. Before more cancer treatment is given, imaging tests, biopsy, or surgery are done to find out if there is cancer and how much there is. Treatment of recurrent childhood highgrade astrocytoma may include the following:  Surgery to remove the tumor.  Highdose chemotherapy with stem cell transplant.  Targeted therapy with a BRAF inhibitor (vemurafenib or dabrafenib).  A clinical trial of targeted therapy with an immune checkpoint inhibitor.  A clinical trial of a new treatment. Check the list of NCIsupported cancer clinical trials that are now accepting patients with recurrent childhood astrocytoma or other tumor of glial origin. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. Talk with your child's doctor about clinical trials that may be right for your child. General information about clinical trials is available from the NCI website.\",\n          \"What are the signs and symptoms of DonnaiBarrow syndrome? The Human Phenotype Ontology provides the following list of signs and symptoms for DonnaiBarrow syndrome. If the information is available, the table below includes how often the symptom is seen in people with this condition. You can use the MedlinePlus Medical Dictionary to look up the definitions for these medical terms. Signs and Symptoms Approximate number of patients (when available) Lowmolecularweight proteinuria 100% Nonacidotic proximal tubulopathy 100% Abnormality of the fontanelles or cranial sutures 90% Aplasia/Hypoplasia of the corpus callosum 90% Broad nasal tip 90% Cognitive impairment 90% Depressed nasal bridge 90% High anterior hairline 90% Hypertelorism 90% Infraorbital crease 90% Lowset, posteriorly rotated ears 90% Myopia 90% Proptosis 90% Proteinuria 90% Sensorineural hearing impairment 90% Short nose 90% Lowset ears 75% Broad forehead 50% Congenital diaphragmatic hernia 50% Diaphragmatic eventration 50% Macrocephaly 50% Omphalocele 50% Retinal detachment 50% Umbilical hernia 50% Visual impairment 50% Progressive visual loss 33% Retinal dystrophy 33% Abnormality of female internal genitalia 7.5% Chorioretinal coloboma 7.5% Hypoplasia of the iris 7.5% Intestinal malrotation 7.5% Iris coloboma 7.5% Seizures 7.5% Ventricular septal defect 7.5% Bicornuate uterus 5% Cataract 1% Aplasia/Hypoplasia of the corpus callosum 11/11 Hypertelorism 12/12 Sensorineural hearing impairment 5/5 Severe Myopia 5/5 Short nose 9/11 Wide anterior fontanel 9/12 Congenital diaphragmatic hernia 9/13 Posteriorly rotated ears 7/11 Iris coloboma 3/6 Omphalocele 6/12 Intestinal malrotation 3/13 Autosomal recessive inheritance  Hypoplasia of midface  Malar flattening  Partial agenesis of the corpus callosum  The Human Phenotype Ontology (HPO) has collected information on how often a sign or symptom occurs in a condition. Much of this information comes from Orphanet, a European rare disease database. The frequency of a sign or symptom is usually listed as a rough estimate of the percentage of patients who have that feature. The frequency may also be listed as a fraction. The first number of the fraction is how many people had the symptom, and the second number is the total number of people who were examined in one study. For example, a frequency of 25/25 means that in a study of 25 people all patients were found to have that symptom. Because these frequencies are based on a specific study, the fractions may be different if another group of patients are examined. Sometimes, no information on frequency is available. In these cases, the sign or symptom may be rare or common.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"Focus\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 10537,\n        \"samples\": [\n          \"Boric acid poisoning\",\n          \"Bili lights\",\n          \"Nitroglycerin Topical\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}","type":"dataframe","variable_name":"med_df"},"text/html":["\n","  <div id=\"df-5e074549-28d2-4f36-b9a0-21b8e6daf4d5\" class=\"colab-df-container\">\n","    <div>\n","<style scoped>\n","    .dataframe tbody tr th:only-of-type {\n","        vertical-align: middle;\n","    }\n","\n","    .dataframe tbody tr th {\n","        vertical-align: top;\n","    }\n","\n","    .dataframe thead th {\n","        text-align: right;\n","    }\n","</style>\n","<table border=\"1\" class=\"dataframe\">\n","  <thead>\n","    <tr style=\"text-align: right;\">\n","      <th></th>\n","      <th>Question</th>\n","      <th>Answer</th>\n","      <th>Focus</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <th>0</th>\n","      <td>What is (are) A guide to clinical trials for c...</td>\n","      <td>None</td>\n","      <td>A guide to clinical trials for cancer</td>\n","    </tr>\n","    <tr>\n","      <th>1</th>\n","      <td>what research (or clinical trials) is being do...</td>\n","      <td>None</td>\n","      <td>A guide to clinical trials for cancer</td>\n","    </tr>\n","    <tr>\n","      <th>2</th>\n","      <td>what research (or clinical trials) is being do...</td>\n","      <td>None</td>\n","      <td>A guide to clinical trials for cancer</td>\n","    </tr>\n","  </tbody>\n","</table>\n","</div>\n","    <div class=\"colab-df-buttons\">\n","\n","  <div class=\"colab-df-container\">\n","    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-5e074549-28d2-4f36-b9a0-21b8e6daf4d5')\"\n","            title=\"Convert this dataframe to an interactive table.\"\n","            style=\"display:none;\">\n","\n","  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n","    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n","  </svg>\n","    </button>\n","\n","  <style>\n","    .colab-df-container {\n","      display:flex;\n","      gap: 12px;\n","    }\n","\n","    .colab-df-convert {\n","      background-color: #E8F0FE;\n","      border: none;\n","      border-radius: 50%;\n","      cursor: pointer;\n","      display: none;\n","      fill: #1967D2;\n","      height: 32px;\n","      padding: 0 0 0 0;\n","      width: 32px;\n","    }\n","\n","    .colab-df-convert:hover {\n","      background-color: #E2EBFA;\n","      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n","      fill: #174EA6;\n","    }\n","\n","    .colab-df-buttons div {\n","      margin-bottom: 4px;\n","    }\n","\n","    [theme=dark] .colab-df-convert {\n","      background-color: #3B4455;\n","      fill: #D2E3FC;\n","    }\n","\n","    [theme=dark] .colab-df-convert:hover {\n","      background-color: #434B5C;\n","      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n","      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n","      fill: #FFFFFF;\n","    }\n","  </style>\n","\n","    <script>\n","      const buttonEl =\n","        document.querySelector('#df-5e074549-28d2-4f36-b9a0-21b8e6daf4d5 button.colab-df-convert');\n","      buttonEl.style.display =\n","        google.colab.kernel.accessAllowed ? 'block' : 'none';\n","\n","      async function convertToInteractive(key) {\n","        const element = document.querySelector('#df-5e074549-28d2-4f36-b9a0-21b8e6daf4d5');\n","        const dataTable =\n","          await google.colab.kernel.invokeFunction('convertToInteractive',\n","                                                    [key], {});\n","        if (!dataTable) return;\n","\n","        const docLinkHtml = 'Like what you see? Visit the ' +\n","          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n","          + ' to learn more about interactive tables.';\n","        element.innerHTML = '';\n","        dataTable['output_type'] = 'display_data';\n","        await google.colab.output.renderOutput(dataTable, element);\n","        const docLink = document.createElement('div');\n","        docLink.innerHTML = docLinkHtml;\n","        element.appendChild(docLink);\n","      }\n","    </script>\n","  </div>\n","\n","\n","<div id=\"df-4c3888d0-7e3d-4c9d-9b55-4ebb22633643\">\n","  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-4c3888d0-7e3d-4c9d-9b55-4ebb22633643')\"\n","            title=\"Suggest charts\"\n","            style=\"display:none;\">\n","\n","<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n","     width=\"24px\">\n","    <g>\n","        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n","    </g>\n","</svg>\n","  </button>\n","\n","<style>\n","  .colab-df-quickchart {\n","      --bg-color: #E8F0FE;\n","      --fill-color: #1967D2;\n","      --hover-bg-color: #E2EBFA;\n","      --hover-fill-color: #174EA6;\n","      --disabled-fill-color: #AAA;\n","      --disabled-bg-color: #DDD;\n","  }\n","\n","  [theme=dark] .colab-df-quickchart {\n","      --bg-color: #3B4455;\n","      --fill-color: #D2E3FC;\n","      --hover-bg-color: #434B5C;\n","      --hover-fill-color: #FFFFFF;\n","      --disabled-bg-color: #3B4455;\n","      --disabled-fill-color: #666;\n","  }\n","\n","  .colab-df-quickchart {\n","    background-color: var(--bg-color);\n","    border: none;\n","    border-radius: 50%;\n","    cursor: pointer;\n","    display: none;\n","    fill: var(--fill-color);\n","    height: 32px;\n","    padding: 0;\n","    width: 32px;\n","  }\n","\n","  .colab-df-quickchart:hover {\n","    background-color: var(--hover-bg-color);\n","    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n","    fill: var(--button-hover-fill-color);\n","  }\n","\n","  .colab-df-quickchart-complete:disabled,\n","  .colab-df-quickchart-complete:disabled:hover {\n","    background-color: var(--disabled-bg-color);\n","    fill: var(--disabled-fill-color);\n","    box-shadow: none;\n","  }\n","\n","  .colab-df-spinner {\n","    border: 2px solid var(--fill-color);\n","    border-color: transparent;\n","    border-bottom-color: var(--fill-color);\n","    animation:\n","      spin 1s steps(1) infinite;\n","  }\n","\n","  @keyframes spin {\n","    0% {\n","      border-color: transparent;\n","      border-bottom-color: var(--fill-color);\n","      border-left-color: var(--fill-color);\n","    }\n","    20% {\n","      border-color: transparent;\n","      border-left-color: var(--fill-color);\n","      border-top-color: var(--fill-color);\n","    }\n","    30% {\n","      border-color: transparent;\n","      border-left-color: var(--fill-color);\n","      border-top-color: var(--fill-color);\n","      border-right-color: var(--fill-color);\n","    }\n","    40% {\n","      border-color: transparent;\n","      border-right-color: var(--fill-color);\n","      border-top-color: var(--fill-color);\n","    }\n","    60% {\n","      border-color: transparent;\n","      border-right-color: var(--fill-color);\n","    }\n","    80% {\n","      border-color: transparent;\n","      border-right-color: var(--fill-color);\n","      border-bottom-color: var(--fill-color);\n","    }\n","    90% {\n","      border-color: transparent;\n","      border-bottom-color: var(--fill-color);\n","    }\n","  }\n","</style>\n","\n","  <script>\n","    async function quickchart(key) {\n","      const quickchartButtonEl =\n","        document.querySelector('#' + key + ' button');\n","      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n","      quickchartButtonEl.classList.add('colab-df-spinner');\n","      try {\n","        const charts = await google.colab.kernel.invokeFunction(\n","            'suggestCharts', [key], {});\n","      } catch (error) {\n","        console.error('Error during call to suggestCharts:', error);\n","      }\n","      quickchartButtonEl.classList.remove('colab-df-spinner');\n","      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n","    }\n","    (() => {\n","      let quickchartButtonEl =\n","        document.querySelector('#df-4c3888d0-7e3d-4c9d-9b55-4ebb22633643 button');\n","      quickchartButtonEl.style.display =\n","        google.colab.kernel.accessAllowed ? 'block' : 'none';\n","    })();\n","  </script>\n","</div>\n","\n","    </div>\n","  </div>\n"],"text/plain":["                                            Question Answer  \\\n","0  What is (are) A guide to clinical trials for c...   None   \n","1  what research (or clinical trials) is being do...   None   \n","2  what research (or clinical trials) is being do...   None   \n","\n","                                   Focus  \n","0  A guide to clinical trials for cancer  \n","1  A guide to clinical trials for cancer  \n","2  A guide to clinical trials for cancer  "]},"execution_count":67,"metadata":{},"output_type":"execute_result"}],"source":["med_df.head(3)"]},{"cell_type":"code","execution_count":null,"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"executionInfo":{"elapsed":4,"status":"ok","timestamp":1710880784886,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"rzOt_5iwYcj4","outputId":"74f57f12-fa9d-4f12-ba50-c83b05e0176d"},"outputs":[{"name":"stdout","output_type":"stream","text":["47441\n","31034\n","0\n"]}],"source":["# check no answer rows\n","print(len(med_df))\n","print(len(med_df[med_df['Answer'].isnull()]))\n","print(len(med_df[med_df['Answer'] == '']))\n","df_to_save = med_df[med_df['Answer'].notnull()]"]},{"cell_type":"code","execution_count":null,"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"executionInfo":{"elapsed":169,"status":"ok","timestamp":1710880800024,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"ZzewBjvEaNsQ","outputId":"abebcfff-aad2-4850-a791-efc420ccc7d9"},"outputs":[{"name":"stdout","output_type":"stream","text":["16407\n"]}],"source":["print(len(df_to_save))"]},{"cell_type":"code","execution_count":null,"metadata":{"id":"012WVAKVY7rU"},"outputs":[],"source":["df_to_save.to_csv('./dataset/MedQuAD.csv', index=False)"]},{"cell_type":"markdown","metadata":{"id":"EdnclD3tr4y0"},"source":["# 2. Generate insights"]},{"cell_type":"code","execution_count":6,"metadata":{"executionInfo":{"elapsed":673,"status":"ok","timestamp":1712361380331,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"E3El2aXosM3r"},"outputs":[],"source":["import pandas as pd\n","import numpy as np\n","\n","import matplotlib.pyplot as plt"]},{"cell_type":"code","execution_count":7,"metadata":{"executionInfo":{"elapsed":2526,"status":"ok","timestamp":1712361399439,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"dNRhrNagr8YZ"},"outputs":[],"source":["m_path = './dataset/MedQuAD.csv'\n","i_path = './dataset/iCliniq.csv'\n","\n","m_df = pd.read_csv(m_path)\n","i_df = pd.read_csv(i_path)"]},{"cell_type":"code","execution_count":18,"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":352},"executionInfo":{"elapsed":2291,"status":"ok","timestamp":1712361866622,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"faHJTLYksV-t","outputId":"30537c1d-0395-497a-bcbb-e35df2f77087"},"outputs":[{"data":{"image/png":"iVBORw0KGgoAAAANSUhEUgAABSwAAAGJCAYAAACAdX2qAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjcuMSwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/bCgiHAAAACXBIWXMAAA9hAAAPYQGoP6dpAABS20lEQVR4nO3de3zP9f//8ft755MZYSPMQiLkFPYJOa8sKSqnnCU+U05RPskhFSmnSuloComSCsVyljktiyipHCo2SjPHbbbn7w+/vb7eNmyzeb/Y7Xq57PLp9Xw93q/34/V+vd/Pb997r4PDGGMEAAAAAAAAADbg5uoGAAAAAAAAACATgSUAAAAAAAAA2yCwBAAAAAAAAGAbBJYAAAAAAAAAbIPAEgAAAAAAAIBtEFgCAAAAAAAAsA0CSwAAAAAAAAC2QWAJAAAAAAAAwDYILAEAAAAAAADYBoElAABwmQoVKqhnz56ubuOG98orr+iWW26Ru7u7atWq5ep2sti/f78cDoeio6Nd3QpwWWvWrJHD4dCnn37q6lYAALihEVgCAIB8ER0dLYfDoW3btmW7vmnTpqpevfpVv8+yZcs0duzYq95OYbFixQqNGDFCd911l2bNmqWXXnrpkrU9e/aUw+FQYGCgzpw5k2X93r175XA45HA49OqrrxZk25bvvvtODz74oIKDg+Xt7a0KFSqof//++uOPP/Jl+0lJSfLx8ZHD4dBPP/2UbU3m55L5FxAQoFtuuUUPPfSQPvvsM2VkZOT6fUeMGCGHw6GOHTte7S5clypUqKD77rvP1W1c0rx58zRt2jRXtwEAQKFFYAkAAFxmz549evfdd3P1mmXLlmncuHEF1NGNZ9WqVXJzc9P777+v7t27q02bNpet9/Dw0OnTp/XVV19lWTd37lz5+PgUVKtZvP7662rcuLF27typJ554Qm+++aYeeughzZ8/XzVr1tSmTZuu+j0WLlwoh8OhkJAQzZ0795J13t7e+uijj/TRRx9p6tSp6tKli/bu3auHHnpILVq0UHJyco7f0xijjz/+WBUqVNBXX32lEydOXPV+IH8RWAIA4FoElgAAwGW8vb3l6enp6jZy5dSpU65uIVeOHDkiX19feXl55aje29tbLVq00Mcff5xl3bx58xQZGZnfLWbru+++0+DBg9WoUSPt2LFDo0aNUp8+ffTqq68qLi5O3t7e6tChg5KSkq7qfebMmaM2bdqoc+fOmjdv3iXrPDw89Oijj+rRRx/VY489phdeeEE//PCDJkyYoDVr1uixxx7L8XuuWbNGf/75pz744AOdO3dOixYtuqp9sKNz584pNTXV1W0AAIDrFIElAABwmYvvYZmWlqZx48apcuXK8vHx0U033aRGjRopJiZG0vlLc2fMmCFJTpfoZjp16pSGDRumcuXKydvbW1WqVNGrr74qY4zT+545c0ZPPvmkSpQooSJFiuj+++/XX3/9JYfD4XS5+dixY+VwOLR792516dJFxYoVU6NGjSRJO3bsUM+ePXXLLbfIx8dHISEh6t27t/755x+n98rcxi+//KJHH31URYsWVcmSJfXcc8/JGKM//vhD7dq1U2BgoEJCQjR58uQcfXbnzp3T+PHjVbFiRetS6f/9739KSUmxahwOh2bNmqVTp05Zn1VO7hPZpUsXff31105h4NatW7V371516dIl29ckJSVp8ODB1mdfqVIlvfzyy1kul05KSlLPnj1VtGhRBQUFqUePHtmGjuPHj5fD4dDs2bPl5+fntK5ixYqaNGmSDh06pHfeeccab9q0qZo2bZplWz179lSFChWyjB88eFDr169Xp06d1KlTJ+3bt08bN2689AeTjWeeeUatW7fWwoUL9csvv+ToNXPnzlW1atXUrFkztWzZMtszOzPvlbhgwQK9+OKLKlu2rHx8fNSiRQv9+uuvTrV79+5Vhw4dFBISIh8fH5UtW1adOnXS8ePHJUnt27dXnTp1nF7Ttm1bORwOffnll9bY5s2b5XA49PXXX1tjOTmumfcgffXVVzVt2jTrO7l79+4cfR6XM2fOHNWtW1e+vr4qXry4OnXqlOV2AJm3m9i9e7eaNWsmPz8/3XzzzZo0aVKW7R04cED333+//P39VapUKQ0ZMkTLly+Xw+HQmjVrrO0tXbpUBw4csH43F39/MjIyrnhcAABA3nm4ugEAAHBjOX78uP7+++8s42lpaVd87dixYzVhwgT17dtX9evXV3JysrZt26bvv/9erVq10uOPP65Dhw4pJiZGH330kdNrjTG6//77tXr1avXp00e1atXS8uXLNXz4cP3111+aOnWqVduzZ08tWLBA3bp1U8OGDbV27drLnjn48MMPq3LlynrppZes8DMmJka///67evXqpZCQEO3atUvvvPOOdu3apU2bNjkFqZLUsWNHVa1aVRMnTtTSpUv1wgsvqHjx4nr77bfVvHlzvfzyy5o7d66eeuop3XnnnWrSpMllP6u+fftq9uzZeuihhzRs2DBt3rxZEyZM0E8//aTPP/9ckvTRRx/pnXfe0ZYtW/Tee+9Jkv7zn/9c8Ti0b99e/fv316JFi9S7d29J58+uvO2227IEX5J0+vRp3X333frrr7/0+OOPq3z58tq4caNGjhypw4cPW5fWGmPUrl07bdiwQf3791fVqlX1+eefq0ePHlm2t3LlSjVu3FhhYWHZ9tixY0f169dPX331lUaMGHHFfcrOxx9/LH9/f913333y9fVVxYoVNXfu3Bx9Rhfq1q2bVqxYoZiYGN16662XrU1JSdFnn32mYcOGSZI6d+6sXr16KSEhQSEhIVnqJ06cKDc3Nz311FM6fvy4Jk2apK5du2rz5s2SpNTUVEVERCglJUVPPPGEQkJC9Ndff2nJkiVKSkpS0aJF1bhxY33xxRdKTk5WYGCgjDH67rvv5ObmpvXr1+v++++XJK1fv15ubm666667JOX8uGaaNWuWzp49q379+snb21vFixfP1ed4sRdffFHPPfecHnnkEfXt21dHjx7V66+/riZNmmj79u0KCgqyav/991/dc889at++vR555BF9+umnevrpp1WjRg3de++9ks7/B43mzZvr8OHDGjRokEJCQjRv3jytXr3a6X2fffZZHT9+XH/++ac1bwQEBOTquAAAgKtkAAAA8sGsWbOMpMv+3X777U6vCQ0NNT169LCW77jjDhMZGXnZ94mKijLZ/SvM4sWLjSTzwgsvOI0/9NBDxuFwmF9//dUYY0xcXJyRZAYPHuxU17NnTyPJjBkzxhobM2aMkWQ6d+6c5f1Onz6dZezjjz82ksy6deuybKNfv37W2Llz50zZsmWNw+EwEydOtMb//fdf4+vr6/SZZCc+Pt5IMn379nUaf+qpp4wks2rVKmusR48ext/f/7Lby672oYceMi1atDDGGJOenm5CQkLMuHHjzL59+4wk88orr1ivGz9+vPH39ze//PKL0/aeeeYZ4+7ubg4ePGiM+b9jNGnSJKfPonHjxkaSmTVrltP+DRo06LL91qxZ0xQvXtxavvvuu83dd9+d7X6FhoZmGa9Ro4bp2rWrtfy///3PlChRwqSlpV3yc8nO9u3bjSQzZMiQy/ZrjDGffvqpkWT27t1rjDEmOTnZ+Pj4mKlTpzrVrV692kgyVatWNSkpKdb49OnTjSSzc+dOp/deuHDhJd9z69atRpJZtmyZMcaYHTt2GEnm4YcfNg0aNLDq7r//flO7dm1rOafHNfM7ERgYaI4cOXLFz8CY87/9y/3W9+/fb9zd3c2LL77oNL5z507j4eHhNH733XcbSebDDz+0xlJSUkxISIjp0KGDNTZ58mQjySxevNgaO3PmjLntttuMJLN69WprPDIyMtvvTE6PCwAAuDpcEg4AAPLVjBkzFBMTk+WvZs2aV3xtUFCQdu3apb179+b6fZctWyZ3d3c9+eSTTuPDhg2TMca6zPWbb76RJP33v/91qnviiScuue3+/ftnGfP19bX++ezZs/r777/VsGFDSdL333+fpb5v377WP7u7u6tevXoyxqhPnz7WeFBQkKpUqaLff//9kr1I5/dVkoYOHeo0nnnW3tKlSy/7+pzo0qWL1qxZo4SEBK1atUoJCQmXvBx84cKFaty4sYoVK6a///7b+mvZsqXS09O1bt06q28PDw8NGDDAeq27u3uWzz7zITRFihS5bI9FihTJ8wNrduzYoZ07d6pz587WWOfOnfX3339r+fLludpW5tl3Oell7ty5qlevnipVqiTp/D5ERkZe8oE/vXr1crr/aOPGjSXJ+o4ULVpUkrR8+XKdPn06223Url1bAQEB1nFYv369ypYtq+7du+v777/X6dOnZYzRhg0brO1LOT+umTp06KCSJUte8TPIiUWLFikjI0OPPPKI03uHhISocuXKWc6KDAgI0KOPPmote3l5qX79+k6/pW+++UY333yzdUapJPn4+OTq/qOZrnRcAADA1eGScAAAkK/q16+vevXqZRnPDD0u5/nnn1e7du106623qnr16rrnnnvUrVu3HIWdBw4cUJkyZbKEXFWrVrXWZ/6vm5tblkuNMwOk7GR3WfKxY8c0btw4zZ8/X0eOHHFal3nvwAuVL1/eablo0aLy8fFRiRIlsoxffB/Mi2Xuw8U9h4SEKCgoyNrXq9GmTRsVKVJEn3zyieLj43XnnXeqUqVK2r9/f5bavXv3aseOHZcMqzI/nwMHDqh06dJZLq+tUqWK03LmMbxSAHjixAmVKlUqp7vkZM6cOfL399ctt9xi3XvQx8dHFSpU0Ny5c3P1cKGTJ0869X0pSUlJWrZsmQYOHOh0v8O77rpLn332mX755Zcsl5Rf/L0pVqyYpPOXQEvnv5tDhw7VlClTNHfuXDVu3Fj333+/db9U6XwoHB4ervXr10s6H1g2btxYjRo1Unp6ujZt2qTg4GAdO3bMKbDM6XHNdKnL9/Ni7969MsaocuXK2a6/+GFdZcuWzXIbhmLFimnHjh3W8oEDB1SxYsUsdZf77V/KlY4LAAC4OgSWAADANpo0aaLffvtNX3zxhVasWKH33ntPU6dO1cyZM53OULzWLjybMtMjjzyijRs3avjw4apVq5YCAgKUkZGhe+65J8uDZqTzoVFOxiRleUjQpVwcvOQnb29vtW/fXrNnz9bvv//u9DCii2VkZKhVq1aXvJfkle7reLHKlSvLw8PDKWy6WEpKivbs2aP69etbYw6HI9vPLj093WnZGKOPP/5Yp06dUrVq1bLUHzlyRCdPnswSrF7Kjz/+KOnKwdfChQuVkpKiyZMnZ/twpblz52rcuHFOYzn5jkyePFk9e/a0fjdPPvmkJkyYoE2bNqls2bKSpEaNGunFF1/U2bNntX79ej377LMKCgpS9erVtX79egUHB0uSU2CZ2+Oa3e8krzIyMqwHAGX3GVx8bK72t5Rb1/r9AAAobAgsAQCArRQvXly9evVSr169dPLkSTVp0kRjx461AstLhXShoaH69ttvdeLECacz3X7++Wdrfeb/ZmRkaN++fU5nb+XmCb///vuvVq5cqXHjxmn06NHWeF4uZc+LzH3Yu3evdQapJCUmJiopKcna16vVpUsXffDBB3Jzc1OnTp0uWVexYkWdPHlSLVu2vGLfK1euzBIG7tmzx6nOz89PLVq00LfffqsDBw5kuz8LFixQSkqKHn74YWusWLFi2V6Se/EZp2vXrtWff/6p559/3unzk84f2379+mnx4sVOlxhfzkcffSSHw6FWrVpdtm7u3LmqXr26xowZk2Xd22+/rXnz5mUJLHOqRo0aqlGjhkaNGqWNGzfqrrvu0syZM/XCCy9IOh9Epqam6uOPP9Zff/1lBZNNmjSxAstbb73VCi6lnB/XglCxYkUZYxQWFpbrwPtSQkNDtXv3bhljnOaR7H77BfkfAwAAwJVxD0sAAGAbF18KHRAQoEqVKiklJcUa8/f3l3T+8toLtWnTRunp6XrjjTecxqdOnSqHw2E9KTgiIkKS9OabbzrVvf766znuM/PsqovPprr4qckFpU2bNtm+35QpUyQpV5czX06zZs00fvx4vfHGG9k+wTrTI488otjY2Gzv/ZiUlKRz585ZfZ87d05vvfWWtT49PT3bz37UqFEyxqhnz546c+aM07p9+/ZpxIgRKleunLp162aNV6xYUT///LOOHj1qjf3www/67rvvnF6feTn48OHD9dBDDzn9PfbYY6pcufIl7yl5sYkTJ2rFihXq2LHjJS9flqQ//vhD69at0yOPPJLlPR966CH16tVLv/76a66fMp2cnGx9vplq1KghNzc3p99NgwYN5OnpqZdfflnFixfX7bffLul8kLlp0yatXbvW6exKKefHtSC0b99e7u7uGjduXJbfmTHmirdNyE5ERIT++usvffnll9bY2bNn9e6772ap9ff3z/bWDgAA4NrgDEsAAGAb1apVU9OmTVW3bl0VL15c27Zt06effqqBAwdaNXXr1pUkPfnkk4qIiJC7u7s6deqktm3bqlmzZnr22We1f/9+3XHHHVqxYoW++OILDR48WBUrVrRe36FDB02bNk3//POPGjZsqLVr1+qXX36RlLMzqwIDA9WkSRNNmjRJaWlpuvnmm7VixQrt27evAD6VrO644w716NFD77zzjpKSknT33Xdry5Ytmj17th544AE1a9YsX97Hzc1No0aNumLd8OHD9eWXX+q+++5Tz549VbduXZ06dUo7d+7Up59+qv3796tEiRJq27at7rrrLj3zzDPav3+/qlWrpkWLFmUbDDVq1EhTp07V4MGDVbNmTfXs2VOlS5fWzz//rHfffVdubm5avHixgoKCrNf07t1bU6ZMUUREhPr06aMjR45o5syZuv3225WcnCzp/KXkn332mVq1aiUfH59s9+f+++/X9OnTdeTIEesemefOndOcOXMknQ+5Dhw4oC+//FI7duxQs2bN9M4771z2M5o3b56MMU4PfLlQmzZt5OHhoblz56pBgwZX/MwzrVq1SgMHDtTDDz+sW2+9VefOndNHH30kd3d3dejQwarz8/NT3bp1tWnTJrVt29b6njdp0kSnTp3SqVOnsgSWOT2uefXrr79aZ4BeqHbt2oqMjNQLL7ygkSNHav/+/XrggQdUpEgR7du3T59//rn69eunp556Klfv9/jjj+uNN95Q586dNWjQIJUuXVpz5861vgcX/vbr1q2rTz75REOHDtWdd96pgIAAtW3bNs/7CgAAcumaP5ccAADckGbNmmUkma1bt2a7/u677za3336701hoaKjp0aOHtfzCCy+Y+vXrm6CgIOPr62tuu+028+KLL5rU1FSr5ty5c+aJJ54wJUuWNA6Hw1z4rzMnTpwwQ4YMMWXKlDGenp6mcuXK5pVXXjEZGRlO73vq1CkTFRVlihcvbgICAswDDzxg9uzZYySZiRMnWnVjxowxkszRo0ez7M+ff/5pHnzwQRMUFGSKFi1qHn74YXPo0CEjyYwZM+aK2+jRo4fx9/fP0eeUnbS0NDNu3DgTFhZmPD09Tbly5czIkSPN2bNnc/Q+2clJ7b59+4wk88orrziNnzhxwowcOdJUqlTJeHl5mRIlSpj//Oc/5tVXX3U6fv/884/p1q2bCQwMNEWLFjXdunUz27dvN5LMrFmzsrzf+vXrTbt27UyJEiWs412qVClz+PDhbPubM2eOueWWW4yXl5epVauWWb58uenRo4cJDQ01xhjz2WefGUnm/fffv+Q+rlmzxkgy06dPtz4XSdafn5+fqVChgunQoYP59NNPTXp6+mU/M2OMqVGjhilfvvxla5o2bWpKlSpl0tLSzOrVq40ks3DhQqeazM8/87P6/fffTe/evU3FihWNj4+PKV68uGnWrJn59ttvs2x/+PDhRpJ5+eWXncYrVapkJJnffvsty2tyclwv9Z24nNDQUKfP9MK/Pn36WHWfffaZadSokfH39zf+/v7mtttuM1FRUWbPnj1WzaV+Mxce90y///67iYyMNL6+vqZkyZJm2LBh1ndi06ZNVt3JkydNly5dTFBQkJFkbSenxwUAAFwdhzHcGRoAACA+Pl61a9fWnDlz1LVrV1e3g0sYP368Ro8erWeffTbbs/OA3Jo2bZqGDBmiP//8UzfffLOr2wEAAOKScAAAUAidOXMmyxONp02bJjc3NzVp0sRFXSEnnnvuOR06dEgvvviiypcvr379+rm6JVxHLv7tnz17Vm+//bYqV65MWAkAgI1whiUAACh0xo0bp7i4ODVr1kweHh76+uuv9fXXX6tfv356++23Xd0egAJy7733qnz58qpVq5aOHz+uOXPmaNeuXZo7d666dOni6vYAAMD/R2AJAAAKnZiYGI0bN067d+/WyZMnVb58eXXr1k3PPvusPDy4AAW4UU2bNk3vvfee9u/fr/T0dFWrVk0jRoxQx44dXd0aAAC4AIElAAAAAAAAANtwc3UDAAAAAAAAAJCJwBIAAAAAAACAbXCTphzIyMjQoUOHVKRIETkcDle3AwAAAAAAAFxXjDE6ceKEypQpIze3y59DSWCZA4cOHVK5cuVc3QYAAAAAAABwXfvjjz9UtmzZy9YQWOZAkSJFJJ3/QAMDA13cTf5LS0vTihUr1Lp1a3l6erq6HQDXAeYNALnBnAEgt5g3AOQGc8b1ITk5WeXKlbNytsshsMyBzMvAAwMDb9jA0s/PT4GBgfywAeQI8waA3GDOAJBbzBsAcoM54/qSk9st8tAdAAAAAAAAALZBYAkAAAAAAADANggsAQAAAAAAANgGgSUAAAAAAAAA2yCwBAAAAAAAAGAbBJYAAAAAAAAAbIPAEgAAAAAAAIBtEFgCAAAAAAAAsA0CSwAAAAAAAAC2QWAJAAAAAAAAwDYILAEAAAAAAADYhocr33zs2LEaN26c01iVKlX0888/S5LOnj2rYcOGaf78+UpJSVFERITefPNNBQcHW/UHDx7UgAEDtHr1agUEBKhHjx6aMGGCPDz+b9fWrFmjoUOHateuXSpXrpxGjRqlnj17XpN9vJ5UH7tcKemOfN/u/omR+b5NAAAAAAAA3Jhcfobl7bffrsOHD1t/GzZssNYNGTJEX331lRYuXKi1a9fq0KFDat++vbU+PT1dkZGRSk1N1caNGzV79mxFR0dr9OjRVs2+ffsUGRmpZs2aKT4+XoMHD1bfvn21fPnya7qfAAAAAAAAAK7MpWdYSpKHh4dCQkKyjB8/flzvv/++5s2bp+bNm0uSZs2apapVq2rTpk1q2LChVqxYod27d+vbb79VcHCwatWqpfHjx+vpp5/W2LFj5eXlpZkzZyosLEyTJ0+WJFWtWlUbNmzQ1KlTFRERcU33FQAAAAAAAMDluTyw3Lt3r8qUKSMfHx+Fh4drwoQJKl++vOLi4pSWlqaWLVtatbfddpvKly+v2NhYNWzYULGxsapRo4bTJeIREREaMGCAdu3apdq1ays2NtZpG5k1gwcPvmRPKSkpSklJsZaTk5MlSWlpaUpLS8unPbePzH3ydjMFun0AN47M3zW/bwA5wZwBILeYNwDkBnPG9SE3x8elgWWDBg0UHR2tKlWq6PDhwxo3bpwaN26sH3/8UQkJCfLy8lJQUJDTa4KDg5WQkCBJSkhIcAorM9dnrrtcTXJyss6cOSNfX98sfU2YMCHLvTUlacWKFfLz88vz/trd+HoZBbLdZcuWFch2AbheTEyMq1sAcB1hzgCQW8wbAHKDOcPeTp8+neNalwaW9957r/XPNWvWVIMGDRQaGqoFCxZkGyReKyNHjtTQoUOt5eTkZJUrV06tW7dWYGCgy/oqKGlpaYqJidFz29yUkpH/D935cSyX3gM3msx5o1WrVvL09HR1OwBsjjkDQG4xbwDIDeaM60PmFcw54fJLwi8UFBSkW2+9Vb/++qtatWql1NRUJSUlOZ1lmZiYaN3zMiQkRFu2bHHaRmJiorUu838zxy6sCQwMvGQo6u3tLW9v7yzjnp6eN/QXPyXDUSBPCb+RPzOgsLvR50UA+Ys5A0BuMW8AyA3mDHvLzbFx+VPCL3Ty5En99ttvKl26tOrWrStPT0+tXLnSWr9nzx4dPHhQ4eHhkqTw8HDt3LlTR44csWpiYmIUGBioatWqWTUXbiOzJnMbAAAAAAAAAOzDpYHlU089pbVr12r//v3auHGjHnzwQbm7u6tz584qWrSo+vTpo6FDh2r16tWKi4tTr169FB4eroYNG0qSWrdurWrVqqlbt2764YcftHz5co0aNUpRUVHWGZL9+/fX77//rhEjRujnn3/Wm2++qQULFmjIkCGu3HUAAAAAAAAA2XDpJeF//vmnOnfurH/++UclS5ZUo0aNtGnTJpUsWVKSNHXqVLm5ualDhw5KSUlRRESE3nzzTev17u7uWrJkiQYMGKDw8HD5+/urR48eev75562asLAwLV26VEOGDNH06dNVtmxZvffee4qI4L6KAAAAAAAAgN24NLCcP3/+Zdf7+PhoxowZmjFjxiVrQkNDr/gU6qZNm2r79u156hEAAAAAAADAtWOre1gCAAAAAAAAKNwILAEAAAAAAADYBoElAAAAAAAAANsgsAQAAAAAAABgGwSWAAAAAAAAAGyDwBIAAAAAAACAbRBYAgAAAAAAALANAksAAAAAAAAAtkFgCQAAAAAAAMA2CCwBAAAAAAAA2AaBJQAAAAAAAADbILAEAAAAAAAAYBsElgAAAAAAAABsg8ASAAAAAAAAgG14uLoB3PgqPLO0wLa9f2JkgW0bAAAAAAAA1x5nWAIAAAAAAACwDQJLAAAAAAAAALZBYAkAAAAAAADANggsAQAAAAAAANgGgSUAAAAAAAAA2yCwBAAAAAAAAGAbBJYAAAAAAAAAbIPAEgAAAAAAAIBtEFgCAAAAAAAAsA0CSwAAAAAAAAC2QWAJAAAAAAAAwDYILAEAAAAAAADYBoElAAAAAAAAANsgsAQAAAAAAABgGwSWAAAAAAAAAGyDwBIAAAAAAACAbRBYAgAAAAAAALANAksAAAAAAAAAtkFgCQAAAAAAAMA2CCwBAAAAAAAA2AaBJQAAAAAAAADbILAEAAAAAAAAYBsElgAAAAAAAABsg8ASAAAAAAAAgG0QWAIAAAAAAACwDQJLAAAAAAAAALZBYAkAAAAAAADANggsAQAAAAAAANgGgSUAAAAAAAAA2yCwBAAAAAAAAGAbBJYAAAAAAAAAbIPAEgAAAAAAAIBt2CawnDhxohwOhwYPHmyNnT17VlFRUbrpppsUEBCgDh06KDEx0el1Bw8eVGRkpPz8/FSqVCkNHz5c586dc6pZs2aN6tSpI29vb1WqVEnR0dHXYI8AAAAAAAAA5JYtAsutW7fq7bffVs2aNZ3GhwwZoq+++koLFy7U2rVrdejQIbVv395an56ersjISKWmpmrjxo2aPXu2oqOjNXr0aKtm3759ioyMVLNmzRQfH6/Bgwerb9++Wr58+TXbPwAAAAAAAAA54/LA8uTJk+rataveffddFStWzBo/fvy43n//fU2ZMkXNmzdX3bp1NWvWLG3cuFGbNm2SJK1YsUK7d+/WnDlzVKtWLd17770aP368ZsyYodTUVEnSzJkzFRYWpsmTJ6tq1aoaOHCgHnroIU2dOtUl+wsAAAAAAADg0jxc3UBUVJQiIyPVsmVLvfDCC9Z4XFyc0tLS1LJlS2vstttuU/ny5RUbG6uGDRsqNjZWNWrUUHBwsFUTERGhAQMGaNeuXapdu7ZiY2OdtpFZc+Gl5xdLSUlRSkqKtZycnCxJSktLU1pa2tXusu1k7pO3m3FxJ7l3Ix4P4HqQ+dvjNwggJ5gzAOQW8waA3GDOuD7k5vi4NLCcP3++vv/+e23dujXLuoSEBHl5eSkoKMhpPDg4WAkJCVbNhWFl5vrMdZerSU5O1pkzZ+Tr65vlvSdMmKBx48ZlGV+xYoX8/PxyvoPXmfH1MlzdQq4tW7bM1S0AhVpMTIyrWwBwHWHOAJBbzBsAcoM5w95Onz6d41qXBZZ//PGHBg0apJiYGPn4+LiqjWyNHDlSQ4cOtZaTk5NVrlw5tW7dWoGBgS7srGCkpaUpJiZGz21zU0qGw9Xt5MqPYyNc3QJQKGXOG61atZKnp6er2wFgc8wZAHKLeQNAbjBnXB8yr2DOCZcFlnFxcTpy5Ijq1KljjaWnp2vdunV64403tHz5cqWmpiopKcnpLMvExESFhIRIkkJCQrRlyxan7WY+RfzCmoufLJ6YmKjAwMBsz66UJG9vb3l7e2cZ9/T0vKG/+CkZDqWkX1+B5Y18PIDrwY0+LwLIX8wZAHKLeQNAbjBn2Ftujo3LHrrTokUL7dy5U/Hx8dZfvXr11LVrV+ufPT09tXLlSus1e/bs0cGDBxUeHi5JCg8P186dO3XkyBGrJiYmRoGBgapWrZpVc+E2MmsytwEAAAAAAADAPlx2hmWRIkVUvXp1pzF/f3/ddNNN1nifPn00dOhQFS9eXIGBgXriiScUHh6uhg0bSpJat26tatWqqVu3bpo0aZISEhI0atQoRUVFWWdI9u/fX2+88YZGjBih3r17a9WqVVqwYIGWLl16bXcYAAAAAAAAwBW5/CnhlzN16lS5ubmpQ4cOSklJUUREhN58801rvbu7u5YsWaIBAwYoPDxc/v7+6tGjh55//nmrJiwsTEuXLtWQIUM0ffp0lS1bVu+9954iIrj3IQAAAAAAAGA3tgos16xZ47Ts4+OjGTNmaMaMGZd8TWho6BWfFN20aVNt3749P1oEAAAAAAAAUIBcdg9LAAAAAAAAALgYgSUAAAAAAAAA2yCwBAAAAAAAAGAbBJYAAAAAAAAAbIPAEgAAAAAAAIBtEFgCAAAAAAAAsA0CSwAAAAAAAAC2QWAJAAAAAAAAwDYILAEAAAAAAADYBoElAAAAAAAAANsgsAQAAAAAAABgGwSWAAAAAAAAAGyDwBIAAAAAAACAbRBYAgAAAAAAALANAksAAAAAAAAAtkFgCQAAAAAAAMA2CCwBAAAAAAAA2AaBJQAAAAAAAADbILAEAAAAAAAAYBsElgAAAAAAAABsg8ASAAAAAAAAgG0QWAIAAAAAAACwDQJLAAAAAAAAALZBYAkAAAAAAADANggsAQAAAAAAANgGgSUAAAAAAAAA2yCwBAAAAAAAAGAbBJYAAAAAAAAAbIPAEgAAAAAAAIBtEFgCAAAAAAAAsA0CSwAAAAAAAAC2QWAJAAAAAAAAwDYILAEAAAAAAADYBoElAAAAAAAAANsgsAQAAAAAAABgGwSWAAAAAAAAAGyDwBIAAAAAAACAbRBYAgAAAAAAALCNPAWWv//+e373AQAAAAAAAAB5CywrVaqkZs2aac6cOTp79mx+9wQAAAAAAACgkMpTYPn999+rZs2aGjp0qEJCQvT4449ry5Yt+d0bAAAAAAAAgEImT4FlrVq1NH36dB06dEgffPCBDh8+rEaNGql69eqaMmWKjh49mt99AgAAAAAAACgEruqhOx4eHmrfvr0WLlyol19+Wb/++queeuoplStXTt27d9fhw4fzq08AAAAAAAAAhcBVBZbbtm3Tf//7X5UuXVpTpkzRU089pd9++00xMTE6dOiQ2rVrl199AgAAAAAAACgEPPLyoilTpmjWrFnas2eP2rRpow8//FBt2rSRm9v5/DMsLEzR0dGqUKFCfvYKAAAAAAAA4AaXp8DyrbfeUu/evdWzZ0+VLl0625pSpUrp/fffv6rmAAAAAAAAABQueQos9+7de8UaLy8v9ejRIy+bBwAAAAAAAFBI5ekelrNmzdLChQuzjC9cuFCzZ8/O8Xbeeust1axZU4GBgQoMDFR4eLi+/vpra/3Zs2cVFRWlm266SQEBAerQoYMSExOdtnHw4EFFRkbKz89PpUqV0vDhw3Xu3DmnmjVr1qhOnTry9vZWpUqVFB0dnbsdBgAAAAAAAHBN5CmwnDBhgkqUKJFlvFSpUnrppZdyvJ2yZctq4sSJiouL07Zt29S8eXO1a9dOu3btkiQNGTJEX331lRYuXKi1a9fq0KFDat++vfX69PR0RUZGKjU1VRs3btTs2bMVHR2t0aNHWzX79u1TZGSkmjVrpvj4eA0ePFh9+/bV8uXL87LrAAAAAAAAAApQni4JP3jwoMLCwrKMh4aG6uDBgzneTtu2bZ2WX3zxRb311lvatGmTypYtq/fff1/z5s1T8+bNJZ0/s7Nq1aratGmTGjZsqBUrVmj37t369ttvFRwcrFq1amn8+PF6+umnNXbsWHl5eWnmzJkKCwvT5MmTJUlVq1bVhg0bNHXqVEVERORl9wEAAAAAAAAUkDwFlqVKldKOHTuyPAX8hx9+0E033ZSnRtLT07Vw4UKdOnVK4eHhiouLU1pamlq2bGnV3HbbbSpfvrxiY2PVsGFDxcbGqkaNGgoODrZqIiIiNGDAAO3atUu1a9dWbGys0zYyawYPHnzJXlJSUpSSkmItJycnS5LS0tKUlpaWp/2zs8x98nYzLu4k927E4wFcDzJ/e/wGAeQEcwaA3GLeAJAbzBnXh9wcnzwFlp07d9aTTz6pIkWKqEmTJpKktWvXatCgQerUqVOutrVz506Fh4fr7NmzCggI0Oeff65q1aopPj5eXl5eCgoKcqoPDg5WQkKCJCkhIcEprMxcn7nucjXJyck6c+aMfH19s/Q0YcIEjRs3Lsv4ihUr5Ofnl6v9u56Mr5fh6hZybdmyZa5uASjUYmJiXN0CgOsIcwaA3GLeAJAbzBn2dvr06RzX5imwHD9+vPbv368WLVrIw+P8JjIyMtS9e/dc3cNSkqpUqaL4+HgdP35cn376qXr06KG1a9fmpa18M3LkSA0dOtRaTk5OVrly5dS6dWsFBga6sLOCkZaWppiYGD23zU0pGQ5Xt5MrP47lsn7AFTLnjVatWsnT09PV7QCwOeYMALnFvAEgN5gzrg+ZVzDnRJ4CSy8vL33yyScaP368fvjhB/n6+qpGjRoKDQ3N07YqVaokSapbt662bt2q6dOnq2PHjkpNTVVSUpLTWZaJiYkKCQmRJIWEhGjLli1O28t8iviFNRc/WTwxMVGBgYHZnl0pSd7e3vL29s4y7unpeUN/8VMyHEpJv74Cyxv5eADXgxt9XgSQv5gzAOQW8waA3GDOsLfcHJs8PSU806233qqHH35Y9913X57CyuxkZGQoJSVFdevWlaenp1auXGmt27Nnjw4ePKjw8HBJUnh4uHbu3KkjR45YNTExMQoMDFS1atWsmgu3kVmTuQ0AAAAAAAAA9pGnMyzT09MVHR2tlStX6siRI8rIcL734apVq3K0nZEjR+ree+9V+fLldeLECc2bN09r1qzR8uXLVbRoUfXp00dDhw5V8eLFFRgYqCeeeELh4eFq2LChJKl169aqVq2aunXrpkmTJikhIUGjRo1SVFSUdYZk//799cYbb2jEiBHq3bu3Vq1apQULFmjp0qV52XUAAAAAAAAABShPgeWgQYMUHR2tyMhIVa9eXQ5H3i4jPnLkiLp3767Dhw+raNGiqlmzppYvX65WrVpJkqZOnSo3Nzd16NBBKSkpioiI0Jtvvmm93t3dXUuWLNGAAQMUHh4uf39/9ejRQ88//7xVExYWpqVLl2rIkCGaPn26ypYtq/fee08REdz7EAAAAAAAALCbPAWW8+fP14IFC9SmTZurevP333//sut9fHw0Y8YMzZgx45I1oaGhV3xSdNOmTbV9+/Y89QgAAAAAAADg2snTPSwvfFAOAAAAAAAAAOSXPAWWw4YN0/Tp02WMye9+AAAAAAAAABRiebokfMOGDVq9erW+/vpr3X777VkeS75o0aJ8aQ4AAAAAAABA4ZKnwDIoKEgPPvhgfvcCAAAAAAAAoJDLU2A5a9as/O4DAAAAAAAAAPIWWErSuXPntGbNGv3222/q0qWLihQpokOHDikwMFABAQH52SNwSRWeWVog290/MbJAtgsAAAAAAIDLy1NgeeDAAd1zzz06ePCgUlJS1KpVKxUpUkQvv/yyUlJSNHPmzPzuEwAAAAAAAEAhkKenhA8aNEj16tXTv//+K19fX2v8wQcf1MqVK/OtOQAAAAAAAACFS57OsFy/fr02btwoLy8vp/EKFSror7/+ypfGAAAAAAAAABQ+eTrDMiMjQ+np6VnG//zzTxUpUuSqmwIAAAAAAABQOOUpsGzdurWmTZtmLTscDp08eVJjxoxRmzZt8qs3AAAAAAAAAIVMni4Jnzx5siIiIlStWjWdPXtWXbp00d69e1WiRAl9/PHH+d0jAAAAAAAAgEIiT4Fl2bJl9cMPP2j+/PnasWOHTp48qT59+qhr165OD+EBAAAAAAAAgNzIU2ApSR4eHnr00UfzsxcAAAAAAAAAhVyeAssPP/zwsuu7d++ep2YAAAAAAAAAFG55CiwHDRrktJyWlqbTp0/Ly8tLfn5+BJYAAAAAAAAA8iRPTwn/999/nf5OnjypPXv2qFGjRjx0BwAAAAAAAECe5SmwzE7lypU1ceLELGdfAgAAAAAAAEBO5VtgKZ1/EM+hQ4fyc5MAAAAAAAAACpE83cPyyy+/dFo2xujw4cN64403dNddd+VLYwAAAAAAAAAKnzwFlg888IDTssPhUMmSJdW8eXNNnjw5P/oCAAAAAAAAUAjlKbDMyMjI7z4AAAAAAAAAIH/vYQkAAAAAAAAAVyNPZ1gOHTo0x7VTpkzJy1sAAAAAAAAAKITyFFhu375d27dvV1pamqpUqSJJ+uWXX+Tu7q46depYdQ6HI3+6BAAAAAAAAFAo5CmwbNu2rYoUKaLZs2erWLFikqR///1XvXr1UuPGjTVs2LB8bRIAAAAAAABA4ZCne1hOnjxZEyZMsMJKSSpWrJheeOEFnhIOAAAAAAAAIM/yFFgmJyfr6NGjWcaPHj2qEydOXHVTAAAAAAAAAAqnPAWWDz74oHr16qVFixbpzz//1J9//qnPPvtMffr0Ufv27fO7RwAAAAAAAACFRJ7uYTlz5kw99dRT6tKli9LS0s5vyMNDffr00SuvvJKvDQIAAAAAAAAoPPIUWPr5+enNN9/UK6+8ot9++02SVLFiRfn7++drcwAAAAAAAAAKlzxdEp7p8OHDOnz4sCpXrix/f38ZY/KrLwAAAAAAAACFUJ4Cy3/++UctWrTQrbfeqjZt2ujw4cOSpD59+mjYsGH52iAAAAAAAACAwiNPgeWQIUPk6empgwcPys/Pzxrv2LGjvvnmm3xrDgAAAAAAAEDhkqd7WK5YsULLly9X2bJlncYrV66sAwcO5EtjAAAAAAAAAAqfPJ1heerUKaczKzMdO3ZM3t7eV90UAAAAAAAAgMIpT4Fl48aN9eGHH1rLDodDGRkZmjRpkpo1a5ZvzQEAAAAAAAAoXPJ0SfikSZPUokULbdu2TampqRoxYoR27dqlY8eO6bvvvsvvHgEAAAAAAAAUEnk6w7J69er65Zdf1KhRI7Vr106nTp1S+/bttX37dlWsWDG/ewQAAAAAAABQSOT6DMu0tDTdc889mjlzpp599tmC6AkAAAAAAABAIZXrMyw9PT21Y8eOgugFAAAAAAAAQCGXp0vCH330Ub3//vv53QsAAAAAAACAQi5PD905d+6cPvjgA3377beqW7eu/P39ndZPmTIlX5oDAAAAAAAAULjkKrD8/fffVaFCBf3444+qU6eOJOmXX35xqnE4HPnXHQAAAAAAAIBCJVeBZeXKlXX48GGtXr1aktSxY0e99tprCg4OLpDmAAAAAAAAABQuubqHpTHGafnrr7/WqVOn8rUhAAAAAAAAAIVXnh66k+niABMAAAAAAAAArkauAkuHw5HlHpVXc8/KCRMm6M4771SRIkVUqlQpPfDAA9qzZ49TzdmzZxUVFaWbbrpJAQEB6tChgxITE51qDh48qMjISPn5+alUqVIaPny4zp0751SzZs0a1alTR97e3qpUqZKio6Pz3DcAAAAAAACAgpGre1gaY9SzZ095e3tLOh8m9u/fP8tTwhctWpSj7a1du1ZRUVG68847de7cOf3vf/9T69attXv3bmubQ4YM0dKlS7Vw4UIVLVpUAwcOVPv27fXdd99JktLT0xUZGamQkBBt3LhRhw8fVvfu3eXp6amXXnpJkrRv3z5FRkaqf//+mjt3rlauXKm+ffuqdOnSioiIyM1HAAAAAAAAAKAA5Sqw7NGjh9Pyo48+elVv/s033zgtR0dHq1SpUoqLi1OTJk10/Phxvf/++5o3b56aN28uSZo1a5aqVq2qTZs2qWHDhlqxYoV2796tb7/9VsHBwapVq5bGjx+vp59+WmPHjpWXl5dmzpypsLAwTZ48WZJUtWpVbdiwQVOnTiWwBAAAAAAAAGwkV4HlrFmzCqoPSdLx48clScWLF5ckxcXFKS0tTS1btrRqbrvtNpUvX16xsbFq2LChYmNjVaNGDacnlUdERGjAgAHatWuXateurdjYWKdtZNYMHjw42z5SUlKUkpJiLScnJ0uS0tLSlJaWli/7aieZ++Ttxj1JM92IxxnIT5m/EX4rAHKCOQNAbjFvAMgN5ozrQ26OT64Cy4KUkZGhwYMH66677lL16tUlSQkJCfLy8lJQUJBTbXBwsBISEqyaC8PKzPWZ6y5Xk5ycrDNnzsjX19dp3YQJEzRu3LgsPa5YsUJ+fn5530mbG18vw9Ut2MayZctc3QJwXYiJiXF1CwCuI8wZAHKLeQNAbjBn2Nvp06dzXGubwDIqKko//vijNmzY4OpWNHLkSA0dOtRaTk5OVrly5dS6dWsFBga6sLOCkZaWppiYGD23zU0pGXl/iNKN5Mex3CoAuJzMeaNVq1by9PR0dTsAbI45A0BuMW8AyA3mjOtD5hXMOWGLwHLgwIFasmSJ1q1bp7Jly1rjISEhSk1NVVJSktNZlomJiQoJCbFqtmzZ4rS9zKeIX1hz8ZPFExMTFRgYmOXsSkny9va2Hix0IU9Pzxv6i5+S4VBKOoGlpBv6OAP56UafFwHkL+YMALnFvAEgN5gz7C03x8atAPu4ImOMBg4cqM8//1yrVq1SWFiY0/q6devK09NTK1eutMb27NmjgwcPKjw8XJIUHh6unTt36siRI1ZNTEyMAgMDVa1aNavmwm1k1mRuAwAAAAAAAIA9uPQMy6ioKM2bN09ffPGFihQpYt1zsmjRovL19VXRokXVp08fDR06VMWLF1dgYKCeeOIJhYeHq2HDhpKk1q1bq1q1aurWrZsmTZqkhIQEjRo1SlFRUdZZkv3799cbb7yhESNGqHfv3lq1apUWLFigpUuXumzfAQAAAAAAAGTl0jMs33rrLR0/flxNmzZV6dKlrb9PPvnEqpk6daruu+8+dejQQU2aNFFISIgWLVpkrXd3d9eSJUvk7u6u8PBwPfroo+revbuef/55qyYsLExLly5VTEyM7rjjDk2ePFnvvfeeIiK4TyEAAAAAAABgJy49w9IYc8UaHx8fzZgxQzNmzLhkTWho6BWf6ty0aVNt37491z2icKrwTMGdfbt/YmSBbRsAAAAAAOB659IzLAEAAAAAAADgQgSWAAAAAAAAAGyDwBIAAAAAAACAbRBYAgAAAAAAALANAksAAAAAAAAAtkFgCQAAAAAAAMA2CCwBAAAAAAAA2AaBJQAAAAAAAADbILAEAAAAAAAAYBsElgAAAAAAAABsg8ASAAAAAAAAgG0QWAIAAAAAAACwDQJLAAAAAAAAALZBYAkAAAAAAADANggsAQAAAAAAANgGgSUAAAAAAAAA2yCwBAAAAAAAAGAbBJYAAAAAAAAAbIPAEgAAAAAAAIBtEFgCAAAAAAAAsA0CSwAAAAAAAAC2QWAJAAAAAAAAwDYILAEAAAAAAADYBoElAAAAAAAAANsgsAQAAAAAAABgGwSWAAAAAAAAAGyDwBIAAAAAAACAbRBYAgAAAAAAALANAksAAAAAAAAAtkFgCQAAAAAAAMA2CCwBAAAAAAAA2AaBJQAAAAAAAADbILAEAAAAAAAAYBsElgAAAAAAAABsg8ASAAAAAAAAgG0QWAIAAAAAAACwDQJLAAAAAAAAALZBYAkAAAAAAADANggsAQAAAAAAANgGgSUAAAAAAAAA2yCwBAAAAAAAAGAbBJYAAAAAAAAAbIPAEgAAAAAAAIBtEFgCAAAAAAAAsA0CSwAAAAAAAAC2QWAJAAAAAAAAwDYILAEAAAAAAADYhksDy3Xr1qlt27YqU6aMHA6HFi9e7LTeGKPRo0erdOnS8vX1VcuWLbV3716nmmPHjqlr164KDAxUUFCQ+vTpo5MnTzrV7NixQ40bN5aPj4/KlSunSZMmFfSuAQAAAAAAAMgDlwaWp06d0h133KEZM2Zku37SpEl67bXXNHPmTG3evFn+/v6KiIjQ2bNnrZquXbtq165diomJ0ZIlS7Ru3Tr169fPWp+cnKzWrVsrNDRUcXFxeuWVVzR27Fi98847Bb5/AAAAAAAAAHLHw5Vvfu+99+ree+/Ndp0xRtOmTdOoUaPUrl07SdKHH36o4OBgLV68WJ06ddJPP/2kb775Rlu3blW9evUkSa+//rratGmjV199VWXKlNHcuXOVmpqqDz74QF5eXrr99tsVHx+vKVOmOAWbAAAAAAAAAFzPpYHl5ezbt08JCQlq2bKlNVa0aFE1aNBAsbGx6tSpk2JjYxUUFGSFlZLUsmVLubm5afPmzXrwwQcVGxurJk2ayMvLy6qJiIjQyy+/rH///VfFihXL8t4pKSlKSUmxlpOTkyVJaWlpSktLK4jddanMffJ2My7upHC4Eb9DKHwyv8d8nwHkBHMGgNxi3gCQG8wZ14fcHB/bBpYJCQmSpODgYKfx4OBga11CQoJKlSrltN7Dw0PFixd3qgkLC8uyjcx12QWWEyZM0Lhx47KMr1ixQn5+fnncI/sbXy/D1S0UCsuWLXN1C0C+iYmJcXULAK4jzBkAcot5A0BuMGfY2+nTp3Nca9vA0pVGjhypoUOHWsvJyckqV66cWrdurcDAQBd2VjDS0tIUExOj57a5KSXD4ep2bng/jo1wdQvAVcucN1q1aiVPT09XtwPA5pgzAOQW8waA3GDOuD5kXsGcE7YNLENCQiRJiYmJKl26tDWemJioWrVqWTVHjhxxet25c+d07Ngx6/UhISFKTEx0qslczqy5mLe3t7y9vbOMe3p63tBf/JQMh1LSCSwL2o38HULhc6PPiwDyF3MGgNxi3gCQG8wZ9pabY+PSp4RfTlhYmEJCQrRy5UprLDk5WZs3b1Z4eLgkKTw8XElJSYqLi7NqVq1apYyMDDVo0MCqWbdundN18jExMapSpUq2l4MDAAAAAAAAcB2XBpYnT55UfHy84uPjJZ1/0E58fLwOHjwoh8OhwYMH64UXXtCXX36pnTt3qnv37ipTpoweeOABSVLVqlV1zz336LHHHtOWLVv03XffaeDAgerUqZPKlCkjSerSpYu8vLzUp08f7dq1S5988ommT5/udMk3AAAAAAAAAHtw6SXh27ZtU7NmzazlzBCxR48eio6O1ogRI3Tq1Cn169dPSUlJatSokb755hv5+PhYr5k7d64GDhyoFi1ayM3NTR06dNBrr71mrS9atKhWrFihqKgo1a1bVyVKlNDo0aPVr1+/a7ejAAAAAAAAAHLEpYFl06ZNZYy55HqHw6Hnn39ezz///CVrihcvrnnz5l32fWrWrKn169fnuU8AAAAAAAAA14Zt72EJAAAAAAAAoPAhsAQAAAAAAABgGwSWAAAAAAAAAGyDwBIAAAAAAACAbRBYAgAAAAAAALANlz4lHCiMKjyztEC2u39iZIFsFwAAAAAA4FriDEsAAAAAAAAAtkFgCQAAAAAAAMA2CCwBAAAAAAAA2AaBJQAAAAAAAADbILAEAAAAAAAAYBsElgAAAAAAAABsg8ASAAAAAAAAgG0QWAIAAAAAAACwDQJLAAAAAAAAALZBYAkAAAAAAADANggsAQAAAAAAANgGgSUAAAAAAAAA2yCwBAAAAAAAAGAbBJYAAAAAAAAAbIPAEgAAAAAAAIBtEFgCAAAAAAAAsA0CSwAAAAAAAAC2QWAJAAAAAAAAwDYILAEAAAAAAADYBoElAAAAAAAAANsgsAQAAAAAAABgGwSWAAAAAAAAAGzDw9UNAMgfFZ5ZWmDb3j8xssC2DQAAAAAAcCHOsAQAAAAAAABgGwSWAAAAAAAAAGyDwBIAAAAAAACAbRBYAgAAAAAAALANAksAAAAAAAAAtkFgCQAAAAAAAMA2CCwBAAAAAAAA2AaBJQAAAAAAAADbILAEAAAAAAAAYBsElgAAAAAAAABsg8ASAAAAAAAAgG14uLoBAPZX4ZmlBbbt/RMjC2zbAAAAAADg+sMZlgAAAAAAAABsg8ASAAAAAAAAgG1wSTgAlyqoy8251BwAAAAAgOsTgSWAGxL33QQAAAAA4PrEJeEAAAAAAAAAbIMzLAEgl7iMHQAAAACAglOozrCcMWOGKlSoIB8fHzVo0EBbtmxxdUsAAAAAAAAALlBozrD85JNPNHToUM2cOVMNGjTQtGnTFBERoT179qhUqVKubg8AuO8mAAAAAAAqRIHllClT9Nhjj6lXr16SpJkzZ2rp0qX64IMP9Mwzz7i4OwAoWPkdhnq7G02qL1Ufu1wp6Y583XamggpZCYYBAAAAwN4KRWCZmpqquLg4jRw50hpzc3NTy5YtFRsbm6U+JSVFKSkp1vLx48clSceOHVNaWlrBN3yNpaWl6fTp0/JIc1N6RsEEDwBuLB4ZRqdPZxTovFHpqQUFst2C/D98BdUzcL3zdjMaVTtDtZ5dpBT+XeOGsHlkC1e3gBtc5v+P8s8//8jT09PV7dhOgwkrC2zb/L5xPWLOuD6cOHFCkmSMuWJtoQgs//77b6Wnpys4ONhpPDg4WD///HOW+gkTJmjcuHFZxsPCwgqsRwC43nRxdQMArivMGTeWEpNd3QGAgsLvG0BBO3HihIoWLXrZmkIRWObWyJEjNXToUGs5IyNDx44d00033SSH48Y7KyA5OVnlypXTH3/8ocDAQFe3A+A6wLwBIDeYMwDkFvMGgNxgzrg+GGN04sQJlSlT5oq1hSKwLFGihNzd3ZWYmOg0npiYqJCQkCz13t7e8vb2dhoLCgoqyBZtITAwkB82gFxh3gCQG8wZAHKLeQNAbjBn2N+VzqzM5FbAfdiCl5eX6tatq5Ur/+8+HxkZGVq5cqXCw8Nd2BkAAAAAAACACxWKMywlaejQoerRo4fq1aun+vXra9q0aTp16pT11HAAAAAAAAAArldoAsuOHTvq6NGjGj16tBISElSrVi198803WR7EUxh5e3trzJgxWS6DB4BLYd4AkBvMGQByi3kDQG4wZ9x4HCYnzxIHAAAAAAAAgGugUNzDEgAAAAAAAMD1gcASAAAAAAAAgG0QWAIAAAAAAACwDQJLAAAAAAAAALZBYAnNmDFDFSpUkI+Pjxo0aKAtW7a4uiUA18C6devUtm1blSlTRg6HQ4sXL3Zab4zR6NGjVbp0afn6+qply5bau3evU82xY8fUtWtXBQYGKigoSH369NHJkyedanbs2KHGjRvLx8dH5cqV06RJkwp61wAUgAkTJujOO+9UkSJFVKpUKT3wwAPas2ePU83Zs2cVFRWlm266SQEBAerQoYMSExOdag4ePKjIyEj5+fmpVKlSGj58uM6dO+dUs2bNGtWpU0fe3t6qVKmSoqOjC3r3AOSzt956SzVr1lRgYKACAwMVHh6ur7/+2lrPfAHgciZOnCiHw6HBgwdbY8wbhQuBZSH3ySefaOjQoRozZoy+//573XHHHYqIiNCRI0dc3RqAAnbq1CndcccdmjFjRrbrJ02apNdee00zZ87U5s2b5e/vr4iICJ09e9aq6dq1q3bt2qWYmBgtWbJE69atU79+/az1ycnJat26tUJDQxUXF6dXXnlFY8eO1TvvvFPg+wcgf61du1ZRUVHatGmTYmJilJaWptatW+vUqVNWzZAhQ/TVV19p4cKFWrt2rQ4dOqT27dtb69PT0xUZGanU1FRt3LhRs2fPVnR0tEaPHm3V7Nu3T5GRkWrWrJni4+M1ePBg9e3bV8uXL7+m+wvg6pQtW1YTJ05UXFyctm3bpubNm6tdu3batWuXJOYLAJe2detWvf3226pZs6bTOPNGIWNQqNWvX99ERUVZy+np6aZMmTJmwoQJLuwKwLUmyXz++efWckZGhgkJCTGvvPKKNZaUlGS8vb3Nxx9/bIwxZvfu3UaS2bp1q1Xz9ddfG4fDYf766y9jjDFvvvmmKVasmElJSbFqnn76aVOlSpUC3iMABe3IkSNGklm7dq0x5vwc4enpaRYuXGjV/PTTT0aSiY2NNcYYs2zZMuPm5mYSEhKsmrfeessEBgZa88SIESPM7bff7vReHTt2NBEREQW9SwAKWLFixcx7773HfAHgkk6cOGEqV65sYmJizN13320GDRpkjOHfMwojzrAsxFJTUxUXF6eWLVtaY25ubmrZsqViY2Nd2BkAV9u3b58SEhKc5oeiRYuqQYMG1vwQGxuroKAg1atXz6pp2bKl3NzctHnzZqumSZMm8vLysmoiIiK0Z88e/fvvv9dobwAUhOPHj0uSihcvLkmKi4tTWlqa07xx2223qXz58k7zRo0aNRQcHGzVREREKDk52TrrKjY21mkbmTX8uwlw/UpPT9f8+fN16tQphYeHM18AuKSoqChFRkZm+W0zbxQ+Hq5uAK7z999/Kz093enHLEnBwcH6+eefXdQVADtISEiQpGznh8x1CQkJKlWqlNN6Dw8PFS9e3KkmLCwsyzYy1xUrVqxA+gdQsDIyMjR48GDdddddql69uqTzv2kvLy8FBQU51V48b2Q3r2Suu1xNcnKyzpw5I19f34LYJQAFYOfOnQoPD9fZs2cVEBCgzz//XNWqVVN8fDzzBYAs5s+fr++//15bt27Nso5/zyh8CCwBAACQK1FRUfrxxx+1YcMGV7cCwMaqVKmi+Ph4HT9+XJ9++ql69OihtWvXurotADb0xx9/aNCgQYqJiZGPj4+r24ENcEl4IVaiRAm5u7tneapWYmKiQkJCXNQVADvInAMuNz+EhIRkeUDXuXPndOzYMaea7LZx4XsAuL4MHDhQS5Ys0erVq1W2bFlrPCQkRKmpqUpKSnKqv3jeuNKccKmawMBAznoArjNeXl6qVKmS6tatqwkTJuiOO+7Q9OnTmS8AZBEXF6cjR46oTp068vDwkIeHh9auXavXXntNHh4eCg4OZt4oZAgsCzEvLy/VrVtXK1eutMYyMjK0cuVKhYeHu7AzAK4WFhamkJAQp/khOTlZmzdvtuaH8PBwJSUlKS4uzqpZtWqVMjIy1KBBA6tm3bp1SktLs2piYmJUpUoVLgcHrjPGGA0cOFCff/65Vq1aleV2D3Xr1pWnp6fTvLFnzx4dPHjQad7YuXOn03/siImJUWBgoKpVq2bVXLiNzBr+3QS4/mVkZCglJYX5AkAWLVq00M6dOxUfH2/91atXT127drX+mXmjkHH1U3/gWvPnzzfe3t4mOjra7N692/Tr188EBQU5PVULwI3pxIkTZvv27Wb79u1GkpkyZYrZvn27OXDggDHGmIkTJ5qgoCDzxRdfmB07dph27dqZsLAwc+bMGWsb99xzj6ldu7bZvHmz2bBhg6lcubLp3LmztT4pKckEBwebbt26mR9//NHMnz/f+Pn5mbfffvua7y+AqzNgwABTtGhRs2bNGnP48GHr7/Tp01ZN//79Tfny5c2qVavMtm3bTHh4uAkPD7fWnzt3zlSvXt20bt3axMfHm2+++caULFnSjBw50qr5/fffjZ+fnxk+fLj56aefzIwZM4y7u7v55ptvrun+Arg6zzzzjFm7dq3Zt2+f2bFjh3nmmWeMw+EwK1asMMYwXwC4sgufEm4M80ZhQ2AJ8/rrr5vy5csbLy8vU79+fbNp0yZXtwTgGli9erWRlOWvR48exhhjMjIyzHPPPWeCg4ONt7e3adGihdmzZ4/TNv755x/TuXNnExAQYAIDA02vXr3MiRMnnGp++OEH06hRI+Pt7W1uvvlmM3HixGu1iwDyUXbzhSQza9Ysq+bMmTPmv//9rylWrJjx8/MzDz74oDl8+LDTdvbv32/uvfde4+vra0qUKGGGDRtm0tLSnGpWr15tatWqZby8vMwtt9zi9B4Arg+9e/c2oaGhxsvLy5QsWdK0aNHCCiuNYb4AcGUXB5bMG4WLwxhjXHNuJwAAAAAAAAA44x6WAAAAAAAAAGyDwBIAAAAAAACAbRBYAgAAAAAAALANAksAAAAAAAAAtkFgCQAAAAAAAMA2CCwBAAAAAAAA2AaBJQAAAAAAAADbILAEAAAAAAAAYBsElgAAAChwTZs21eDBg13dhkvxGQAAAOQMgSUAAACyOHr0qAYMGKDy5cvL29tbISEhioiI0HfffWfVOBwOLV68OEfbW7RokcaPH19A3f4fO4SCa9askcPhUFJSkkv7AAAAuF55uLoBAAAA2E+HDh2Umpqq2bNn65ZbblFiYqJWrlypf/75J1fbSU1NlZeXl4oXL15AnQIAAOBGwxmWAAAAcJKUlKT169fr5ZdfVrNmzRQaGqr69etr5MiRuv/++yVJFSpUkCQ9+OCDcjgc1vLYsWNVq1YtvffeewoLC5OPj4+krGc+VqhQQS+99JJ69+6tIkWKqHz58nrnnXec+ti4caNq1aolHx8f1atXT4sXL5bD4VB8fHye923Dhg1q3LixfH19Va5cOT355JM6depUvvW1f/9+NWvWTJJUrFgxORwO9ezZ03ptRkaGRowYoeLFiyskJERjx47N874AAADcqAgsAQAA4CQgIEABAQFavHixUlJSsq3ZunWrJGnWrFk6fPiwtSxJv/76qz777DMtWrTosuHi5MmTVa9ePW3fvl3//e9/NWDAAO3Zs0eSlJycrLZt26pGjRr6/vvvNX78eD399NNXtV+//fab7rnnHnXo0EE7duzQJ598og0bNmjgwIH51le5cuX02WefSZL27Nmjw4cPa/r06db62bNny9/fX5s3b9akSZP0/PPPKyYm5qr2CwAA4EZDYAkAAAAnHh4eio6O1uzZsxUUFKS77rpL//vf/7Rjxw6rpmTJkpKkoKAghYSEWMvS+cvAP/zwQ9WuXVs1a9a85Pu0adNG//3vf1WpUiU9/fTTKlGihFavXi1JmjdvnhwOh959911Vq1ZN9957r4YPH35V+zVhwgR17dpVgwcPVuXKlfWf//xHr732mj788EOdPXs2X/pyd3e3Ln8vVaqUQkJCVLRoUWt9zZo1NWbMGFWuXFndu3dXvXr1tHLlyqvaLwAAgBsNgSUAAACy6NChgw4dOqQvv/xS99xzj9asWaM6deooOjr6iq8NDQ11CjAv5cIw0+FwKCQkREeOHJF0/uzEmjVrWpeUS1L9+vVzvyMX+OGHHxQdHW2dQRoQEKCIiAhlZGRo375916SviwPc0qVLW9sGAADAeTx0BwAAANny8fFRq1at1KpVKz333HPq27evxowZ43RPxuz4+/vnaPuenp5Oyw6HQxkZGXlt94pOnjypxx9/XE8++WSWdeXLl78mfV3rfQYAALgecYYlAAAAcqRatWpOD6jx9PRUenp6gbxXlSpVtHPnTqd7aF54n8y8qFOnjnbv3q1KlSpl+fPy8sq3vjK3VVCfDQAAwI2OwBIAAABO/vnnHzVv3lxz5szRjh07tG/fPi1cuFCTJk1Su3btrLoKFSpo5cqVSkhI0L///puvPXTp0kUZGRnq16+ffvrpJy1fvlyvvvqqpPNnJV7O0aNHFR8f7/SXmJiop59+Whs3btTAgQMVHx+vvXv36osvvsjy0J2r7Ss0NFQOh0NLlizR0aNHdfLkyTx+CgAAAIUTgSUAAACcBAQEqEGDBpo6daqaNGmi6tWr67nnntNjjz2mN954w6qbPHmyYmJiVK5cOdWuXTtfewgMDNRXX32l+Ph41apVS88++6xGjx4tSU73j8zOvHnzVLt2bae/d999VzVr1tTatWv1yy+/qHHjxqpdu7ZGjx6tMmXK5GtfN998s8aNG6dnnnlGwcHBuQpEAQAAIDmMMcbVTQAAAABXMnfuXPXq1UvHjx+Xr6+vq9ux2LUvAACA6xUP3QEAAIAtffjhh7rlllt0880364cfftDTTz+tRx55xOWhoF37AgAAuFEQWAIAAMCWEhISNHr0aCUkJKh06dJ6+OGH9eKLL7q6Ldv2BQAAcKPgknAAAAAAAAAAtsFDdwAAAAAAAADYBoElAAAAAAAAANsgsAQAAAAAAABgGwSWAAAAAAAAAGyDwBIAAAAAAACAbRBYAgAAAAAAALANAksAAAAAAAAAtkFgCQAAAAAAAMA2/h/2hP2tR0C/YwAAAABJRU5ErkJggg==","text/plain":["<Figure size 1600x400 with 1 Axes>"]},"metadata":{},"output_type":"display_data"}],"source":["def cnt(row):\n","  return len(row.split())\n","\n","\n","m_df['ans_length'] = m_df['Answer'].apply(cnt)\n","i_df['ans_length'] = i_df['Answer'].apply(cnt)\n","\n","def dis_plot(df, name):\n","  plt.figure(figsize = (16,4))\n","  plt.hist(df['ans_length'], bins=50)\n","  plt.xlabel('String Length')\n","  plt.ylabel('Frequency')\n","  plt.title('Histogram of {} Answer Length'.format(name))\n","  plt.grid(True)\n","  plt.show()\n","\n","dis_plot(m_df, 'MedQuAD')"]},{"cell_type":"code","execution_count":19,"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":352},"executionInfo":{"elapsed":579,"status":"ok","timestamp":1712361867199,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"zCXjsUIis2rX","outputId":"b111643c-4c2c-43c9-8259-516a7be5d0c4"},"outputs":[{"data":{"image/png":"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","text/plain":["<Figure size 1600x400 with 1 Axes>"]},"metadata":{},"output_type":"display_data"}],"source":["dis_plot(i_df, 'iCliniq')"]},{"cell_type":"code","execution_count":17,"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"executionInfo":{"elapsed":183,"status":"ok","timestamp":1712361647950,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"vKSk0UxRtACU","outputId":"ef6aaa67-932f-4e3a-d84c-1c1dbbd1ffb7"},"outputs":[{"name":"stdout","output_type":"stream","text":["mean: 197.68031937587614\n","median:  137.0\n","mean: 90.99529443398764\n","median:  60.0\n"]}],"source":["# check mean and median of each dataset\n","def check_m(df):\n","  print(\"mean:\", df['ans_length'].mean())\n","  print(\"median: \", df['ans_length'].median())\n","\n","check_m(m_df)\n","\n","check_m(i_df)"]},{"cell_type":"code","execution_count":26,"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":53},"executionInfo":{"elapsed":168,"status":"ok","timestamp":1712362821171,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"7uBVsRnGxIsX","outputId":"4827b776-4de7-4c9a-bcbe-27e2711b7792"},"outputs":[{"data":{"application/vnd.google.colaboratory.intrinsic+json":{"type":"string"},"text/plain":["'How is SCOT deficiency diagnosed? Diagnosis of SCOT deficiency is made in people showing the signs and symptoms of the condition and who have absent or reduced SCOT enzyme activity.'"]},"execution_count":26,"metadata":{},"output_type":"execute_result"}],"source":["m_df_sample = m_df[m_df['ans_length'] == 30]\n","\n","m_df_sample.head(3)\n","m_df['Answer'].iloc[5258]"]},{"cell_type":"code","execution_count":30,"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":35},"executionInfo":{"elapsed":170,"status":"ok","timestamp":1712362932146,"user":{"displayName":"Wang Yiwen","userId":"16196898643232130408"},"user_tz":420},"id":"rgB7TXyFx7_o","outputId":"89fc7ba6-e554-4fbe-b4c6-64fb48bd0849"},"outputs":[{"data":{"application/vnd.google.colaboratory.intrinsic+json":{"type":"string"},"text/plain":["\"will brushing my teeth with baking soda and sea salt increase my sodium intake? . i'm on a low sodium diet.\""]},"execution_count":30,"metadata":{},"output_type":"execute_result"}],"source":["i_df_sample = i_df[i_df['ans_length'] == 30]\n","\n","i_df_sample.head(3)\n","i_df['Question'].iloc[88]"]}],"metadata":{"colab":{"authorship_tag":"ABX9TyPh+Ev/F5j6Gtyw85mGaMBO","provenance":[]},"kernelspec":{"display_name":"Python 3","name":"python3"},"language_info":{"name":"python"}},"nbformat":4,"nbformat_minor":0}
